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Abstract 
 
Clostridium difficile is an anaerobic, Gram-positive bacterium which resides in the gut 
of animals and humans. There are over 600 different polymerase chain reaction (PCR) 
ribotypes of C. difficile, some of which are pathogenic. Despite 5% of healthy humans 
having C. difficile within their normal gut microflora, this organism can cause illness in 
the elderly and immunocompromised patients. Symptoms of C. difficile infection (CDI) 
range from mild diarrhoea to death, and are due to two toxins (toxin A and toxin B) 
that the bacterium produces. Treatment for CDI includes the use of antibiotics, such 
as metronidazole and vancomycin, however some antibiotics, such as 
fluoroquinolones, can cause CDI, as they can disrupt the normal gut flora. C. difficile 
also produces biofilms which protect the bacteria within from antibiotic therapy. This 
study evaluated three genetically distinct C. difficile groups, PCR ribotypes 078, 027 
and 002. All these PCR ribotypes cause disease, however PCR ribotypes 078 and 027 
have been stated to be hypervirulent strains, therefore causing more severe illness. 
This study compared: the growth rate and pattern; cytotoxin production; susceptibility 
to a range of antimicrobials; biofilm production; viable and spore counts; and 
antimicrobial susceptibility for the three PCR ribotype groups to determine if any of 
these factors might contribute to the enhanced virulence status of PCR ribotype 078. 
These assays were completed by conducting: batch culture growth curves; cytotoxin 
production assays; antimicrobial susceptibility tests (agar dilution methods); a 
standard 96-well microtitre plate biofilm assay for biofilm quantification; and the 
Calgary Biofilm device (CBD) to assess biofilm formation and susceptibilities to 
metronidazole and vancomycin. This study found PCR ribotype 078 had higher average 
absorbance readings (biomass) than the PCR ribotypes 027 and 002 at the peak of 
growth (8 hours of incubation in an anaerobic cabinet): average OD600 readings for the 
PCR ribotype 078 group were 3.70 whereas the PCR ribotype 027 group had an OD600 
of 2.82 and PCR ribotypes 002 3.26. PCR ribotype 002 had significantly the highest 
average maximum specific growth rate (µmax) (0.73 h-1) whereas PCR ribotype 078 
had the lowest average µmax (0.53 h-1) (P≤0.001). PCR ribotype 078 also had 
significantly higher cytotoxin production than PCR ribotypes 027 and 002, with PCR 
ribotype 078 median cytotoxin titres of 3 log10 relative units (RU) in 72 hour cultures, 
whereas PCR ribotypes 027 and 002 median titres were 1 RU (P≤0.001). All the strains 
in each PCR ribotype group were susceptible to metronidazole and vancomycin. PCR 
ribotype 078 strains were susceptible to most of the antimicrobials used in this study, 
for example the vancomycin and metronidazole geometric mean minimum inhibitory 
concentration (MIC)s for PCR ribotypes 078 were vancomycin: 0.57 mg/L and 
metronidazole: 0.08 mg/L. The results for vancomycin were similar to the other two 
PCR ribotypes (P=0.79) whereas the metronidazole result were significantly different 
(P≤0.001) (PCR ribotypes 027: vancomycin: 0.53 mg/L and metronidazole: 1.37 
mg/L; PCR ribotype 002: vancomycin: 0.53 mg/L and metronidazole: 0.18 mg/L). PCR 
ribotype 078 average biofilm production significantly increased over three (0.12 OD590) 
to six (0.28 OD590) days whereas the average for the PCR ribotype 002 group did 
increase but not significantly (three days: 0.07 OD590 and six days: 0.09 OD590), 
however biofilm production by PCR ribotype 027 strains decreased (three days: 0.11 
OD590 and six days: 0.08 OD590). PCR 078 demonstrated the lowest biofilm total viable 
counts (5.17 log10 colony forming units (CFU)/ml) and spore counts (4.58 log10 
CFU/ml) using a 96-well microtitre plate after six days of growth compared to the 
other two PCR ribotypes in which total viable counts were 5.87 log10/5.70 log10 CFU/ml 
and spore counts were 5.32 log10/5.27 log10 CFU/ml for the PCR ribotype 027/002 
groups respectively (P≤0.001). The biofilm susceptibility testing results showed PCR 
ribotype 078 geometric mean biofilm MIC (bMIC) and minimum biofilm eradication 
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concentrations (MBEC) for vancomycin (0.50 mg/L and 0.57 mg/L respectively) and 
metronidazole (0.50 mg/L and 0.55 mg/L respectively) had similar results to those of 
PCR ribotypes 027 (vancomycin: bMIC 0.50 mg/L and MBEC 0.50 mg/L and 
metronidazole: bMIC 0.50 mg/L and MBEC 0.66 mg/L) and 002 (vancomycin: bMIC 2 
mg/L and MBEC 2 mg/L and metronidazole: bMIC 4 mg/L and MBEC 2 mg/L). Total 
viable counts and spore counts on static CBD were <100 CFU/peg for all PCR ribotypes. 
This study also demonstrated that agitating the CBD in a four day growth period 
facilitated more extensive biofilm formation compared to static CBD assays. This study 
has demonstrated differences in growth (planktonic and biofilm) and cytotoxin 
production between the three C. difficile PCR ribotype groups assessed. These results 
could influence the behaviour and pathogenesis of PCR ribotype 078 in CDI if these 
results translated into the in vivo setting. Further studies are required in order to 
assess the reproducibility of these data in a larger cohort of isolates of the ribotypes 
studied, and in isolates obtained from varied hosts (human and animal) and 
environmental settings.  
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1. Introduction 
 
 
1.1.  Background 
 
Clostridium difficile is a Gram-positive, anaerobic bacterium (Figure 1.1) (Hall and 
O'Toole, 1935). C. difficile can be identified by its rod shape and by using 
polymerase chain reaction (PCR) to find the gluD gene which encodes for the 
enzyme glutamate dehydrogenase (GDH) which is unique to C. difficile (Goorhuis 
et al., 2008). There are now over 600 genetic variants of C. difficile, which can be 
differentiated using PCR ribotyping. These PCR ribotypes vary in virulence, 
susceptibly to antibiotics and the host/environment from which they are commonly 
isolated, such as within the gut of humans and other animals (including pigs and 
horses) and soil (Baverud et al., 2003; Janezic et al., 2012; O'Neill et al., 1996). 
Approximately 5% of healthy adults and about 50% of new born children, have C. 
difficile in their normal gut flora with no symptoms (Donelli et al., 2012; Nelson 
et al., 2011; Tsutsumi et al., 2014). Despite this, C. difficile infection (CDI) still 
occurs, most commonly in the elderly (>65 years old), as the likelihood of 
contracting CDI increases by about 2% for every additional year after 18 years 
old, also in immunocompromised individuals, such as patients undergoing 
chemotherapy, and in patients who are taking certain antibiotics, such as 
clindamycin, ciprofloxacin and aminopenicillins (Best et al., 2012; Borgmann et 
al., 2010; Debast et al., 2014; Lawley et al., 2009; Loo et al., 2011; O'Connor et 
al., 2004; Tsutsumi et al., 2014). Due to highly resistant spores, transmission of 
C. difficile is hard to control, this results in epidemics in the UK and around the 
world (Lawley et al., 2009). CDI patients, in England, can stay in hospitals for up 
to 21 days longer than other patients and costs approximately £7 000 per case 
(Pereira et al., 2014; Wilcox, 2013). C. difficile has two major virulence factors 
which causes CDI, toxin A and toxin B, which result in a range of symptoms, from 
mild diarrhoea to death, depending on the patient and PCR ribotype (Kuehne et 
al., 2010; NHS, 2012; Rupnik et al., 2005; Shen, 2012). This review will look at: 
a brief history of the discovery of C. difficile, the characteristics which define 
different PCR ribotypes with an emphasis on two so called ‘hypervirulent’ PCR 
ribotypes, PCR ribotype 078 and 027, which causes severe illness, as well as a 
virulent PCR ribotype, PCR ribotype 002, how C. difficile infects the host, how 
different treatments and the host’s body work to stop infections and how hospitals 
prevent the spread of CDI (Goorhuis et al., 2008; Tagashira et al., 2013). 
 
1.1.1. History of C. difficile 
 
In 1935 C. difficile was identified and described in the intestinal contents of new-
born babies as part of the gut microflora (Hall and O'Toole, 1935; Jones et al., 
2013). Hall and O'Toole (1935) described this bacterium as being slow-growing 
and having “less striking physiologic properties” compared to Kopfchenbacterien. 
Subsequently, the bacterium was named Bacillus difficilis due to the difficulties 
encountered in isolating and studying the bacterium. In the 1970s, B. difficilis was 
reclassified Clostridium difficile (Goudarzi et al., 2014; Kelly and LaMont, 2008). 
Then in 1978 C. difficile was found to be a cause of a proportion of cases of 
antimicrobial associated diarrhoea and colitis, and most cases of 
pseudomembranous colitis (PMC) (Freeman et al., 2010; Heinlen and Ballard, 
2010). Molecular analysis of all the toxins produced by C. difficile began in the 
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1980s, at which time the genes were sequenced, defined and regulations were 
studied (Rupnik et al., 2005). It has now been proposed, by Yutin and Galperin 
(2013) that C. difficile be reclassified further to Peptoclostridium difficile due to 
finding similarities  between C. difficile 16S rRNA-based phylogeny and DNA 
gyrase (GyrB) to that of the genus Peptostreptococci. 
 
1.1.2. C. difficile Epidemiology  
 
PCR is used to sub-categorise C. difficile into different genotypic groups (PCR 
ribotypes). The process involves using primers to amplify the spacer region 
between the 16S and 23S rRNA genes. The spacer region was discovered to differ 
in length for different ribotypes (Bidet et al., 1999; Gürtler, 1993). This has helped 
to discover over 600 PCR ribotypes of C. difficile. The C. difficile Ribotyping 
Network (CDRN) within Public Health England (PHE) (formally Health Protection 
Agency (HPA)), uses multi-locus variable repeat analysis (MLVA) to further 
differentiate C. difficile isolates within the same PCR ribotype, and this helps to 
determine the prevalence of different PCR ribotypes in the UK (PHE and CDRN, 
2014). Two of major ribotypes of interest are PCR ribotype 027 and 078, which 
have previously both been designated as hypervirulent, which are suggested to 
cause more severe CDI (Goorhuis et al., 2008; Janezic et al., 2012; Stabler et al., 
2009).  
 
PHE has been collecting data on the incidence of CDI from laboratories in England 
and Wales since 1990,and in Northern Ireland since 2001 (HPA, 2013; PHE, 2014). 
The data collected includes the number of toxin-positive faecal samples in a range 
of age groups, in a given year, for both sexes (PHE, 2014). In 1990 there was a 
total of 1194 positive samples in England and Wales: within the decade there was 
a 20-fold increase (20527 samples). When Northern Ireland was included in 2001 
the number of cases increased to 22352 samples (PHE, 2014). In 2007 the number 
of positive samples more than doubled to 57228 (PHE, 2014). After 2007 the 
number of positive samples decreased, to 13547 samples, in 2013, where 40.38% 
were male and 58.40% were female, and over half (57.19%) of the positive 
sample were from the 75 and over age group (PHE, 2014). The prevalence of 
different ribotypes has changed between 2007 and 2013, for example PCR 
ribotype 002 prevalence has increased overall since 2007 (30.8% to 7.69%), 
however it has decreased between 2012 (10%) and 2013 (7.69%). PCR ribotype 
078 has also increased in prevalence since 2007 (2.31%) to 2013 (14.62%), 
however, PCR ribotype 027 has decreased overall since 2007 to 2013 (63.85% to 
5.38%), but between 2012 (3.85%) and 2013 (5.38%) there was a slight increase 
in prevalence (PHE and CDRN, 2014). In the rest of Europe 8% of CDI was the 
result of PCR ribotype 078, whereas, only 5% of CDI was due to PCR ribotype 027 
(Kurka et al., 2014). 
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Figure 1.1. Gram stain of C. difficile (x1000 magnification) observed under a light 
microscope. Showing the Gram-positive (purple) rod shaped C. difficile.  
 
 Scale 10.00 µm 
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PCR ribotype 027 was first isolated in Quebec, Canada, in 2003, since then 
outbreaks of CDI caused by PCR ribotype 027 have spread to Europe and Asia 
(Stabler et al., 2009). In the UK, the first outbreak was at Stoke Mandeville 
hospital, Buckinghamshire, in 2004/05 (Brazier, 2012; Stabler et al., 2009). The 
hypervirulent status of PCR ribotype 027 was thought to be due to a mutation 
within the tcdC gene, which was a putative negative regulator for toxin production 
(MacCannell et al., 2006; Murray et al., 2009). MacCannell et al. (2006) were the 
first to report the 18-base pair (bp) tcdC deletion. This study retrieved PCR 
ribotype 027 isolates and used PCR to identify the genes associated with virulence: 
tcdA (encodes for toxin A), tcdB (encodes for toxin B), cdtA, cdtB (both encode C. 
difficile transferase (CDT) and the erythromycin resistance methyltransferase 
(ermB) genes in all strains. They also amplified and sequenced the tcdC gene. 
MacCannell et al. (2006) found that all strains in the study had tcdA, tcdB, cdtA, 
cdtB and ermB genes, and an 18-bp deletion within the 330 to 347 positions of 
the tcdC gene. The tcdC gene also had another frameshift mutation, which was 
undocumented before this study, at position 117. These mutations were 
hypothesised by MacCannell et al. (2006) to contribute to the reported 
hypervirulence of PCR ribotype 027 as it causes the PCR ribotype to produce toxin 
in its exponential phase of growth (MacCannell et al., 2006). However, there are 
still uncertainties on how the mutation in the tcdC gene affects toxin production 
in PCR ribotype 027. For example, Warny et al. (2005) found that PCR ribotype 
027 has elevated levels of toxin A and toxin B, whereas Freeman et al. (2007) 
found PCR ribotype 027 produces cytotoxin for longer, than PCR ribotype 001. 
Cartman et al. (2012) used a strain of PCR ribotypes 027 (R20291) and 
manipulated the tcdC gene to ascertain if the gene has an effect on toxin 
production. The study found no differences in toxin production between any of the 
strains, with wild-type tcdC or with introduced mutations. However, Deakin et al. 
(2012) then found the increase in toxin production could be due to a mutation 
within the spo0A gene and pondered if the gene negativity regulates toxin 
production.  
 
PCR ribotype 078 is another, hypervirulent PCR ribotype which has been shown to 
be an increasing cause of CDI in humans (Goorhuis et al., 2008; Janezic et al., 
2012). Goorhuis et al. (2008) defined PCR ribotype 078 as hypervirulent due to 
its increase in prevalence in humans as well as its similarities to PCR ribotype 027, 
which has be proven to be hypervirulent (Valiente et al., 2012). Goorhuis et al. 
(2008) had come to this conclusion by conducting a three year study collecting 
human isolates from hospitals, care homes and other healthcare facilities in The 
Netherlands and Europe, as well as isolates collected from pigs. C. difficile was 
identified by PCR and the strains were further studied, via PCR ribotyping and 
toxinotyping, to find the presence of tcdA, tcdB and the cdt genes and to find 
mutations in tcdC (Bakker et al., 2012; Goorhuis et al., 2008). Antimicrobial 
susceptibility testing was also conducted to find how resistant the isolates were to 
moxifloxacin, ciprofloxacin, clindamycin and erythromycin, and MLVA was 
performed to assess the genetic relatedness between isolates. The authors found 
that all of the isolates studied contained all four genes (tcdA, tcdB and both the 
cdt genes) and a 39-bp deletion in tcdC. The susceptibility tests of the PCR 
ribotype 078 isolates (41 human and 8 pig) revealed that 57% were susceptible 
(MICs <4 mg/L) to clindamycin, 78% were resistant to erythromycin (≥4 mg/L) 
and 14% of the isolates contained the ermB gene which encodes for resistance to 
other antibiotics, such as erythromycin (Corso et al., 2009; Spigaglia et al., 2005). 
With the fluoroquinolones, 94% of C. difficile were resistant (MICs ≥4 mg/L) to 
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ciprofloxacin and 88% were resistant to moxifloxacin. There was no significant 
difference between pig and human isolates in susceptibility to the antibiotics 
evaluated in this study. The MLVA analysis demonstrated that all the isolates were 
genetically related.Goorhuis et al. (2008) also gave questionnaires to CDI patients 
infected with different PCR ribotypes and 715 were returned; 57 were infected 
with PCR ribotype 078, 129 patients were infected with PCR ribotype 027 and the 
rest of the patients were infected with other PCR ribotypes other than PCR ribotype 
078 and 027. The questionnaire responses were compared for each PCR ribotype 
and the authors reported that the patients infected with PCR ribotype 078 were 
younger and their symptoms were just as severe as PCR ribotype 027. The 
questionnaire results also suggested that PCR ribotype 078 infected patients, in 
comparison to patients with other strains of C. difficile, were less likely to have 
other diseases and more frequently had received fluoroquinolone therapy. This 
study concluded that due to the severity and similarities to PCR ribotype 027, PCR 
ribotype 078 was a hypervirulent strain. However the study did not state what 
facets constitute a hypervirulent strain and did not test the magnitude of toxin 
production (Goorhuis et al., 2008; Shen, 2012).The study also did not assess the 
susceptibility to antimicrobials which are used to treat CDI, such as vancomycin 
and metronidazole (Debast et al., 2014).  
 
1.1.3. C. difficile Infection 
 
The main symptom of CDI is diarrhoea, which is defined as: 1) passing three or 
more stools per day which correspond to types five to seven on the Bristol stool 
chart, or 2) passing more loose stools per day than is normal for an individual. 
Diarrhoea can occur up to two months after antibiotic treatment for another 
condition (Debast et al., 2014; WHO, 2013; Wilcox, 2003). The diarrhoea usually 
has a foul odour and may contain (although rare) blood (Bartlett and Gerding, 
2008; Bennett et al., 1984). In more severe cases of CDI PMC can occur, this is 
identified by the visualisation of yellow/white plaques (pseudomembranes) along 
the colon wall, which are detectible via colonoscopy (or sigmoidoscopy), or 
histopathology (Debast et al., 2014; Johal et al., 2004; Wilcox, 2003). The 
mortality rate of CDI patients is 17% after 30 days from the start of infection 
(Wilcox, 2013). This could be due to the development of toxic megacolon when 
the patient also has PMC, this condition is rare but noticeable by the dilation of 
the colon (Autenrieth and Baumgart, 2012; Wilcox, 2003). Despite treatment 
there is about a 20% chance of CDI recurring within one to eight weeks, but has 
been known to take place up to 12 weeks after antibiotic treatment is completed 
for an initial episode. CDI recurrence may be due to persistence of C. difficile 
spores which are resistant to antibiotics, and the normal gut microflora not being 
able to grow back to normal after CDI to restore colonisation resistance (Bakken 
et al., 2011; Debast et al., 2014; Im et al., 2011). 
 
1.1.4. C. difficile Sporulation and Germination 
 
Sporulation occurs when the environment changes so the C. difficile cannot 
survive, such as the introduction of antibiotics or a limitation in nutrients (Joshi et 
al., 2012; Oka et al., 2012). Spores are excreted in the faeces of an infected 
person and are easily transmitted between patients this is due to their resistance 
to aerobic conditions and many disinfectants (Deakin et al., 2012; Heeg et al., 
2012; Lawley et al., 2009; Paredes-Sabja and Sarker, 2011; Wheeldon et al., 
2008a).The environmental stresses cause sensor kinases to phosphorylate the 
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proteins involved in sporulation, one of which is encoded by the spo0A gene 
(Deakin et al., 2012; Saujet et al., 2011; Underwood et al., 2009). Sporulation 
starts when a mother cell divides and then engulfs the spore which matures inside 
the cell until the cell denatures. The spore lays dormant until it is exposed to bile 
salts within the colon (Figure 1.2.) (Higgins and Dworkin, 2012; Paredes-Sabja et 
al., 2014; Sorg and Sonenshein, 2008; Wheeldon et al., 2008a). The spore goes 
through different phases, including the dark-phase where the spore becomes less 
resistant to environmental changes such as antibiotics and heat, the spore grows 
out into a vegetative cell (Figure 1.2.) (Liu et al., 2014; Nerandzic and Donskey, 
2013). Merrigan et al. (2010) found that hypervirulent strains of C. difficile 
produce more spores (after 48 hours) than non-hypervirulent strains. One gene 
which is recognised as a contributor in this process is the spo0A gene. This initiates 
sporulation by activing RNA polymerase sigma factors needed for sporulation to 
occur (Paredes-Sabja et al., 2014). Deakin et al. (2012) found sporulation was 
decreased in spo0A mutant strains of 630Δerm and R20291 (compared to wild-
type strains), and that complementation of the spo0A into the mutant restored 
the wild-type phenotype. 
 
Germination is the transition from a phase bright spore into a phase dark spore. 
This occurs when the spore is in the ideal environment for vegetative C. difficile 
to survive (Figure 1.2.) (Setlow, 2003; Sorg and Sonenshein, 2008). Germination 
has been studied in other Clostridium species, such as C. perfringens, however 
due to differences in germination triggers it is difficult to predict how germination 
is induced in C. difficile spores (Paredes-Sabja and Sarker, 2011; Paredes-Sabja 
et al., 2014). For example, Paredes-Sabja and Sarker (2011) found C. difficile 
spores do not germinate when incubated with epithelial cells (in vitro) whereas C. 
perfringens spores did. This may be due to C. difficile spores having different  
germination receptors than spores of other Clostridium species (Ramirez et al., 
2010). Known germination triggers of C. difficile spores are primary bile salts, 
such as sodium taurocholate (Sorg and Sonenshein, 2008). Sorg and Sonenshein 
(2008) treated C. difficile spores with 0.1 %  sodium taurocholate in supplemented 
Brain Heart Infusion solution, serially diluted then cultured onto agar, their results 
showed a mean colony forming unit (CFU) recovery of 1.27%. Wheeldon et al. 
(2008a) found the optimal concentrations of sodium taurocholate for germination 
were between 0.1 and 100 mmol/L. Germination is also induced by secondary bile 
salts, such as deoxycholate (Sorg and Sonenshein, 2008). Deoxycholate has also 
been found to induce germination by Sorg and Sonenshein (2008), using the same 
methods as the sodium taurocholate. The study showed a mean CFU recovery of 
1.48% with deoxycholate, which was similar to the recovery of CFUs with sodium 
taurocholate in the same study. When Sorg and Sonenshein (2008) exposed 
vegetative cells to deoxycholate, it was found that growth was inhibited. 
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Figure 1.2. The cycle of sporulation from vegetative cell to spore, when environmental conditions are not preferable 
to the bacterial cell, and back to vegetative cell, when exposed to bile salts. (Based on figures presented in Higgins 
and Dworkin (2012) and Liu et al. (2014)). 
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1.1.5. The Toxins of C. difficile  
 
The symptoms of CDI are caused by two toxins, toxin A and toxin B, which are 
the major virulence factors of C. difficile and are produced by PCR ribotype 078, 
027 and 002 (Carter et al., 2010; Kuehne et al., 2010; Lyras et al., 2009; Rupnik 
et al., 2005; Shen, 2012; Tagashira et al., 2013). These toxins are 
glucosyltransferases, which catalyse glycosylation of the Rho/Rac family of 
GTPases within gut epithelial cells, this in turn causes the actin cytoskeleton to 
become unregulated and consequently the cell structure is adversely affected (the 
cells become rounded), cell-cell junctions are lost due to a disruption in signalling 
and the end result is cell death (Kuehne et al., 2010; Liu et al., 2014; Lyras et al., 
2009; Pruitt et al., 2010; Shen, 2012). Two studies used similar methods to 
determine which toxin was more active however the results from these studies 
were contradictory (Kuehne et al., 2010; Lyras et al., 2009). Lyras et al. (2009) 
used human colon carcinoma (HT29) cells and African green monkey kidney (Vero) 
cells in cytotoxicity assays and exposed them to different toxins produced by C. 
difficile whose genes were mutated to stop them being functional (Kuehne et al., 
2010). The C. difficile strains used, either had the toxin A gene (tcdA gene) 
mutated, so toxin A was not produced (A-B+), or the toxin B gene (tcdB gene) 
mutated, so toxin B was not produced (A+B-), or a wild-type parent PCR ribotype 
which possessed both fully functional toxin genes (Lyras et al., 2009). Lyras et al. 
(2009) stated that the A+B- strain, produced more toxin A than the wild-type. 
Toxin A, from the A+B- strain, was found to be less toxic to the HT29 than the 
toxin A from the wild-type strain, and the toxin B, from the A-B+ strain, was less 
toxic than the toxin B from the wild-type strain. However the toxin B (A-B+) was 
just as toxic to the Vero cells as the wild-type strains toxin A, and the toxin A 
(A+B-) was less toxic to Vero cells than the toxin B (A-B+) and the wild-type 
strain. Hamster models were used to see which toxin was more active in vivo, by 
colonising the hamsters with the different toxin variants of C. difficile. The 
researchers found that the strain which only produced toxin B (A-B+) maintained 
a virulent phenotype of the wild-type strain, however the strain producing just 
toxin A (A+B-) was virulent, thus suggesting the C. difficile does not need both 
toxins to be virulent (Lyras et al., 2009). Conversely, Kuehne et al. (2010) used 
a parental strain (A+B+), a strain which only produced toxin A (A+B-), a strain 
which only produce toxin B (A-B+) and a strain with a double-toxin mutation (A-
B-). The study showed that the A-B- strain culture supernatant had no effect on 
the HT29 cells and Vero cells. The A-B+ toxin preparation had a reduced effect on 
both cell lines and the A+B- preparation had an increased effect on both cell types, 
however the results were not significant. The study went on to use hamsters which 
the authors infected with all the C. difficile strains, and all hamsters except those 
infected with the A-B- C. difficile strain showed symptoms, suggesting that both 
toxins are needed for C. difficile virulence (Kuehne et al., 2010). 
 
Some C. difficile PCR ribotypes produce a third toxin, a C. difficile transferase 
(CDT), which has been proposed to aid in the colonisation and adhesion of C. 
difficile to the epithelial cells on the gut wall (Carman et al., 2011; Geric et al., 
2006; Schwan et al., 2009). CDT is a binary toxin, composed of two unlinked 
molecules designated CDTa and CDTb. CDTb (encoded by the cdtB gene) binds to 
lipolysis-stimulated lipoprotein receptors (LSR) on the host cell which causes them 
to cluster and create lipid rafts which helps form a pre-pore. CDTa (encoded by 
the cdtA gene) is the enzyme component of the binary toxin and binds to the pre-
pore and is up taken into the cell via endocytosis. Acidification, an influx of 
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hydrogen ions, of the endosome induces the release of the CDTa into the cytosol. 
The polymerisation of the cellular actin is inhibited by this process, which leads to 
a disrupted actin cytoskeleton and the formation of long microtubule protrusions 
through the cell membrane, increasing the adherence and potentially colonisation 
of C. difficile (Aktories et al., 2012; Carman et al., 2011; Carter et al., 2007; Geric 
et al., 2006; McDonald et al., 2005; Papatheodorou et al., 2013; Rupnik et al., 
2003; Shen, 2012). C. difficile strains expressing CDT alone are not virulent. Geric 
et al. (2006) conducted a study to determine the likely contribution of CDT to C. 
difficile virulence. The study used hamsters and gave them clindamycin to disrupt 
the gut bacterial flora. On the fifth day after the administration of clindamycin, 
the hamsters were colonised with one of four strains of C. difficile, three were 
toxin A and toxin B negative and CDT positive (A-B-CDT+) and one strain was 
toxin A/B positive and CDT negative (A+B+CDT-), which was the positive control. 
The study found the hamsters which were colonised with the A-B-CDT+ strains 
remained colonised for the rest of the study (27 days, after clindamycin 
administration) with no symptoms, whereas, the control hamsters died the day 
after the colonisation of the A+B+CDT- C. difficile strain. Geric et al. (2006) 
concluded the CDT does not cause disease on its own, and hypothesised CDT may 
play another role in the virulence of strains which produce toxin A and B. This 
alternate role was studied by Schwan et al. (2009), who inoculated human 
intestinal epithelial cell line (Caco-2) with CDT. The study found when the Caco-2 
cells were inoculated with CDT, the toxin induced the production of microtubule 
protrusions along the cell boarder, which created a mesh after two hours of being 
exposed to CDT. The study then inoculated the Caco-2 cells with CDT then, after 
an hour, introduced a C. difficile strain which produced only toxin A and toxin B. 
After 90 minutes the cell culture was washed and an antibody, which detected C. 
difficile surface proteins and was used to see if any C. difficile cells remained 
(Schwan et al., 2009). The study found that C. difficile remained in the cell culture, 
therefore, Schwan et al. (2009) concluded that CDT induced microtubules which 
may aid in the adhesion of the C. difficile to the gut wall. 
 
1.1.6. Diagnosis of CDI 
 
As C. difficile is not always the cause of diarrhoea after antibiotic use, a two or 
three stage algorithm is performed to diagnose CDI (Beaugerie and Petit, 2004; 
Debast et al., 2014; Wilcox, 2003). This algorithm is low cost and has a quick 
turnaround time however the tests involved have not been standardised and are 
not sensitive when used separately (Debast et al., 2014; Kvach et al., 2010). The 
algorithm involves conducting an enzyme immunoassay to detect the presence of 
GDH in a stool sample (Debast et al., 2014; Kim et al., 2014). This antigen, unique 
to C. difficile, indicates the presence of C. difficile but not if the strain is toxigenic 
for toxin A and B (Debast et al., 2014; Goorhuis et al., 2008; Kim et al., 2014). If 
the sample is positive for GDH, the next stage is to test for toxins, this is done by 
performing cytotoxin assays on the faecal samples this confirms or refutes the 
presence of toxin A and B (Debast et al., 2014; Kvach et al., 2010; Quinn et al., 
2010). Another method to diagnose CDI, if samples are GDH positive, is to perform 
a nucleic acid amplification test (NAAT), these tests are more sensitive than the 
toxin assays and work by using PCR to detect the tcdB gene within the samples 
(Debast et al., 2014; Gould et al., 2013). Gould et al. (2013) found that when 
diagnostic laboratories switched from using cytotoxin assays to NAAT the 
percentage of CDI incidence increased by 24%. 
 
 10 
  
1.1.7. The Immune Response to C. difficile   
 
The gut has innate mechanisms to keep bacterial homeostasis and defend against 
pathogenic bacteria, involving a mucus layer, epithelial cells and immune cells 
(Kurashima et al., 2013). The mucus layer contains antimicrobial peptides (AMP) 
and immunoglobulin (Ig) A antibodies (Kurashima et al., 2013). Below the mucus 
layer are epithelial cells, such as goblet and Paneth cells, which produce the AMPs 
and transport IgA via transcytosis through the columnar epithelial cell from the 
immune cells (Johal et al., 2004; Kurashima et al., 2013; Zasloff, 2002). The 
immune cells include mast cells, which support the production of IgA, innate 
lymphoid cells, which instigate the inflammatory response by AMP production and 
regulates tissue repair, as well as plasma cells which produce IgA antibodies 
(Kurashima et al., 2013; Shapiro-Shelef et al., 2003). IgA antibodies are the 
frontline defence if any pathogen is present within the gut, and in agreement with 
this, Olson et al. (2013) demonstrated IgA to be effective against C. difficile toxin 
A. They found this by inoculating HT29 cells with toxin A and IgA to see how the 
antibodies affected the toxins uptake in the cells. They found that IgA not only 
decreased the uptake of toxins into the HT29 cells but also decreased the effects 
of toxin A on the permeability of the HT29 cells (Olson et al., 2013). Additionally, 
IgA opsonises bacteria to aid removal from the gut (Bollinger et al., 2003). IgG 
and IgM antibodies are produced by B lymphocytes and these antibodies are also 
important in the immune response against toxins A and B (Kyne et al., 2000; 
McDonnell et al., 1990; Qiu et al., 2003; Torres et al., 1995). 
 
1.1.8. Colonisation Resistance Against CDI 
 
The normal gut microflora is an important defence against CDI, so-called 
colonisation resistance (Nelson et al., 2011). There are approximately 1011 
bacteria/g of faeces within the human colon, including the genera Escherichia, 
Streptococcus and Clostridium (Ridlon et al., 2006). If C. difficile is introduced, 
through the transmission of highly resistant spores, the stable resident bacteria 
can inhibit C. difficile from overgrowing (Taur and Pamer, 2014). Once the spores 
have reached the colon, germination is triggered by the exposure to primary bile 
salts, such as sodium taurocholate, which are produced by the liver (Sorg and 
Sonenshein, 2008; Wheeldon et al., 2008a). In a healthy colon, without 
antibiotics, vegetative C. difficile cells are inhibited due to the production of the 
secondary bile salt deoxycholate, which is converted from taurocholic acid by 
bacteria within the gut, such as Bifidobacterium, Streptococcus and Clostridium 
species (not including C. difficile) (Grill et al., 1995; Sorg and Sonenshein, 2008; 
Taur and Pamer, 2014). Bifidobacterium species produce bile salt hydrolase 
(BSH), these enzymes hydrolyse the amide bonds of bile salts, which are created 
when cholesterol conjugates to either glycine or taurine in the liver, to produce 
secondary bile salt acids and amino acids (Grill et al., 1995; Sorg and Sonenshein, 
2008; Taranto et al., 1999). The gut bacteria, including C. difficile, also help to 
reinforce the host’s gut defences, by the production of short chain fatty acids 
(SCFA), one example is butyrate (Pryde et al., 2002). Butyrate, like other SCFA, 
has been found to help in increasing tight junction protein expression, this 
decreases epithelial lining permeability, it also has anti-inflammatory properties 
and increases mucin and AMP production (Antharam et al., 2013; Muñoz‐Tamayo 
et al., 2011; Pryde et al., 2002). Butyrate-producing bacteria, such as C. difficile 
and C. acetobutylicum, have been found to convert acetoacetyl-CoA to acetyl-CoA 
and butyrate using butyryl-CoA:acetate-CoA transferase (Duncan et al., 2002; 
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Muñoz‐Tamayo et al., 2011; Pryde et al., 2002). Roseburia intestinalis and R. 
inulinivorans use β-fructofuranosidase to produce butyrate using oligosaccharides 
and polysaccharides (Scott et al., 2011; Shahinas et al., 2012). When antibiotics 
are given to a patient they can suppress these microbes in the gut, which 
decreases deoxycholate production this promotes the vegetative C. difficile cells 
to grow causing an infection (Nelson et al., 2011; Shahinas et al., 2012; Taur and 
Pamer, 2014). 
 
1.1.9. Treatment of CDI 
 
There are three main antibiotics that are used as treatments for CDI, 
metronidazole and vancomycin, which have been used for more than 30 years and 
are the first-line treatments for CDI, along with fidaxomicin which is a new 
antimicrobial agent recently licensed for the treatment of CDI (Debast et al., 2014; 
Johnson and Wilcox, 2012; Wu et al., 2013). Metronidazole is a nitroimidazole 
compound which has a major role in treating anaerobic bacterial infections 
(Menendez et al., 2002). The drug is usually administered in the form of a 450 mg 
oral tablet three times a day for 10 days for the first recurrence of mild or 
moderate cases of CDI (Debast et al., 2014; Freeman et al., 1997). Metronidazole 
has been found to be mutagenic to bacterial DNA and causes the DNA to 
breakdown by denaturing its helical structure (Edwards, 1980; Menendez et al., 
2002). Vancomycin is a glycopeptide compound which is produced by 
Amycolatopsis orientalis and is used to treat Gram-positive bacterial infections 
and enterocolitis which is caused by C. difficile (Losey et al., 2001; Nagarajan, 
1991). This drug is administered orally, 125 mg four times a day for 10 days for 
non-severe, severe and re-occurring CDI (Al-Nassir et al., 2008; Debast et al., 
2014). Vancomycin inhibits the maintenance of the bacterial cell wall by inhibiting 
peptidoglycan synthesis (Nagarajan, 1991; Yim et al., 2014). Fidaxomicin is a 
narrow spectrum macrocyclic antibiotic which inhibits transcription by binding to 
DNA-dependent RNA polymerase to inhibit RNA synthesis in the bacteria 
(Babakhani et al., 2013; Johnson and Wilcox, 2012; Louie et al., 2011). This 
antibiotic is taken orally as a 200 mg tablet twice a day for 10 days for initial 
severe and non-severe CDI as well as recurrent infection (Debast et al., 2014). In 
C. difficile it was found that fidaxomicin can inhibit spore formation, but also may 
potentially reduce the spread of CDI to other patients (Babakhani et al., 2013). 
Additionally, Babakhani et al. (2013) also found that fidaxomicin inhibits 
transcription of the toxin A and B genes. Fidaxomicin has been found to be eight 
times more effective than vancomycin against C. difficile in vitro, and reduces the 
chance the recurrence of CDI (Babakhani et al., 2013; Louie et al., 2011). 
 
Other non-antibiotic based treatments for CDI exist, including faecal microbiota 
transplantation (FMT) and other probiotic therapies, and the use of these 
treatments depend on severity of illness, the PCR ribotype, the patient, and 
whether a CDI episode is a recurrence or not (Debast et al., 2014). FMT involves 
restoring normal gut microflora by transplanting healthy stool, via faecal enema 
or nasogastric administration, which can re-establish normal gut microflora along 
with normal gut function (Bakken et al., 2011). It is hypothesised that bacteria, 
introduced from the healthy faeces, could convert taurocholic acid to choline which 
is then converted to deoxycholate, by other bacteria, which inhibits C. difficile 
vegetative cell growth (Sorg and Sonenshein, 2008; Taur and Pamer, 2014). FMT 
was first used as a treatment for CDI in 1983 and since then there has been a 
success rate of 96% in treating CDI (Bakken et al., 2011). Despite this apparent 
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efficacy, FMT remains controversial as pathogens could be transferred as well as 
microbes which influence other conditions, such as obesity, autoimmune diseases 
and metabolic syndromes (Taur and Pamer, 2014). Studies have been performed 
to find the bacteria which are involved in these processes so to make the treatment 
safer and easier to administer (Taur and Pamer, 2014). Shahinas et al. (2012) 
conducted a study to see which bacterial species are present in the gut after FMT 
treatment. Stool samples were taken from CDI patients before FMT was conducted 
(but after vancomycin treatment), and then 14 days after successful treatment 
more samples were acquired and frozen for 24 hours. The V5-V6 regions of the 
bacterial 16S rRNA were analysed to find the bacterial taxa present within the 
stool sample before and after treatment. The study found low diversity but high 
abundance of the taxa present, such as Proteobacteria, in the pre-treatment 
samples, there was also a low numbers of Lachnospiraceae, which if not present 
in the gut is thought to prolong CDI (Shahinas et al., 2012; Taur and Pamer, 
2014). After successful treatment samples had higher diversity and more 
Firmicutes, Bacteroidetes and Bacteroides species as well as increased populations 
of R. intestinalis and R. inulinivorans. These bacteria could be linked to treatment 
of CDI via FMT due to the normalisation of gut microflora and the production of 
bile salts, which inhibits C. difficile growth, and butyrate which has been linked 
with tissue repair and development (Shahinas et al., 2012; Taur and Pamer, 
2014). 
 
Probiotics are a possible prevention strategy for CDI (including recurrence) and 
are given in some cases with antibiotics (Debast et al., 2014; McFarland, 2009). 
Probiotics are defined by the World Health Organization (WHO) and the Food and 
Agriculture Organization of the United Nations (FAO), as “Live microorganisms 
which when administered in adequate amounts confer a health benefit on the host” 
(WHO and FAO, 2001). Like FMT, probiotics are used to help re-establish the 
microflora within the gut after antibiotic treatment (McFarland, 2009). This 
prevention method involves using living bacteria, such as Lactobacillus, 
Clostridium, Streptococcus and Bifidobacterium species, and fungal species, such 
as Saccharomyces boulardii (Debast et al., 2014; Johnson et al., 2012). As this 
treatment involves different organisms there are different modes of action 
(McFarland, 2009). For example, S. boulardii is a yeast species isolated from fruit, 
like lychees, which produces a protease which have been shown, in vitro, to 
degrade the C. difficile toxins and inhibits the toxins from binding to the gut wall 
receptors (Johnson et al., 2012). It has also been suggested to inhibit the 
adherence of C. difficile cells in vitro, for example Tasteyre et al. (2002) found 
that S. boulardii reduced the adherence of C. difficile to Vero cells by 34% 
(compared to the control). Trejo et al. (2006) found that several Bifidobacterium 
species, including B. pseudolongum, B. longum and B. bifidum, produced lactic 
acid and acetic acid. These supernatants were found to inhibit growth of all the C. 
difficile strains (in vitro) as well as decrease the adhesion of some strains of C. 
difficile used (Trejo et al., 2006). However, there are some disadvantages to using 
probiotics, for example there is an increased risk to immunocompromised patients 
as infection with the probiotic organism could occur (Debast et al., 2014; 
McFarland, 2009; Wada et al., 2010). Riquelme et al. (2003) reported two case 
studies where the patients had conditions which resulted in immunodeficiency, 
both patients contracted CDI so were given S. boulardii as treatment. In both 
cases treatment had to be ceased, as the S. boulardii caused a fever and was 
found in blood cultures taken from the two patients (Riquelme et al., 2003). 
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1.1.10. Antimicrobial Susceptibilities of C. difficile 
 
Antimicrobial resistance is quickly becoming a major problem in the world, and if 
new treatments for bacterial infections are not discovered soon antibiotics will 
become obsolete (WHO, 2014). Some C. difficile PCR ribotypes have developed 
resistance to certain groups of antibiotics, this resistance can result into an 
increased risk of CDI in patients as well as a recurrence of CDI (McDonald et al., 
2005; Nelson et al., 2011). As antibiotics used to treat other infections could 
inhibit the gut microflora allowing the resistance C. difficile to thrive (Nelson et 
al., 2011). Resistance to metronidazole and vancomycin is seldom seen in C. 
difficile, however, susceptibly to metronidazole has be found, by Chong et al. 
(2014), to be reducing in strains of PCR ribotype 027, in vitro. Additionally, Leeds 
et al. (2013) found some strains of C. difficile have developed reduced susceptibly 
to vancomycin and fidaxomicin, in vitro. Resistance to fluoroquinolones has also 
developed in certain PCR ribotypes, such as PCR ribotype 078 and 027, this has 
led to an increase in prevalence of CDI in patients receiving fluoroquinolone 
treatment (Goorhuis et al., 2008; He et al., 2013; Solomon et al., 2011; Vardakas 
et al., 2012).   
  
1.1.11. Infection Control Procedures for C. difficile 
 
NHS hospitals operate strict protocols in the control and prevention of CDI. If a 
patient is suspected of having CDI then the ‘SIGHT’ mnemonic protocol is used 
(Appendix 1.1). All unnecessary antibiotics and drugs, which cause diarrhoea, 
should be ceased, the patient is kept in isolation, and their fluid, nutrition and 
electrolyte replacement is reviewed daily until the diarrhoea has stopped for 48 
hours. The patient’s hospital room should be cleaned with chlorine-containing 
cleaning agents daily and any bedding treated as contaminated (DH and HPA, 
2008). 
 
One possible prevention measure to reduce the spread of C. difficile is the use of 
copper. The antimicrobial properties of copper have been known of since the time 
of the ancient Egyptians, at about 2600 BC, who used the metal to sterilise chest 
wounds and drinking water. Since then the benefits of using bronze or brass door 
knobs in hospitals and using copper vessels to carry drinking water in developing 
countries have been documented (Grass et al., 2011). The contact with the copper 
is what triggers the killing of bacteria, as the copper dissolves the ions produced 
damage the cell wall, then catalysis the production of reactive oxygen species 
(ROS), in the form of hydroxyl radicals, which causes damage to the DNA, in turn 
causes the bacterial cell to die (Grass et al., 2011; Hong et al., 2012; Molteni et 
al., 2010). As C. difficile has highly resistant spores to normal cleaning procedures, 
it is hard to control the spread of infection, so using copper could potentially help 
(Weaver et al., 2008). Weaver et al. (2008) inoculated copper, copper alloy and 
stainless steel (as a control) coupons with C. difficile vegetative cells and spores 
and spores alone. The coupons were incubated at room temperature in aerobic 
conditions for a range of time points. Once incubated the cultures were transferred 
into phosphate buffer solution (PBS) so they could be spread onto agar plates, 
which were incubated anaerobically and the concentration of C. difficile CFUs were 
counted. This study found that the initial cell death occurred in the first three 
hours, this was believed to be due to the aerobic conditions (glass coupons had 
the same results). However, the coupons with higher copper content (including 
100% copper) had higher death rates with both the vegetative and spores and 
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spore cultures alone (Weaver et al., 2008). Wheeldon et al. (2008b) also 
compared the effect of copper and stainless steel on C. difficile vegetative cells 
and spores from two strains (PCR ribotype 027 and NCTC 11204). However, the 
vegetative cell tests were conducted in anaerobic conditions and the spore 
experiments were performed in aerobic conditions. D/E neutralizer was added to 
neutralise the copper at 30 minute intervals (for three hours). The spores were 
then suspended in molten Fastidious Anaerobe Agar (supplemented with sodium 
taurocholate) and left to stand at room temperature, whereas the vegetative cells 
were inoculated onto Wilkins Chalgren agar and incubated anaerobically at 37°C. 
Some of the spores were then inoculated again onto copper after being exposed 
to the sodium taurocholate and then cultured onto Wilkins Chalgren agar. This 
study found that copper did have a reduced number of vegetative cells after 30 
minutes. Contrastingly, Wheeldon et al. (2008b) found copper had no effect to C. 
difficile spores not exposed to sodium taurocholate, however, the spores, from 
both strains, which were exposed to the bile salt had a lower number of viable 
cells on the copper than the stainless steel after 60 minutes. This suggests that 
the copper has antimicrobial effects on germinating spores. These results can be 
translated into real-world applications as spores which have been through the 
body have been exposed to bile salts which aids germination, therefore if copper 
surfaces were used in hospitals it is likely to reduce the spread of C. difficile 
(Wheeldon et al., 2008a; Wheeldon et al., 2008b). 
 
1.2. Aim and Objectives 
 
The main aim of this study is to characterise in vitro factors that may contribute 
to the virulence of PCR ribotype 078 and comparator strains of PCR ribotype 027 
and 002. 
 
 Growth and toxin production for each PCR ribotype (over 72 hours) will be 
compered by producing batch culture growth curves and acquiring toxin 
samples for Vero cell cytotoxicity assays. 
 
 The susceptibility for each PCR ribotype to eight antimicrobial agents will be 
tested using the agar incorporation method (AIM) to produce minimum 
inhibitory concentration (MIC).  
 
 The biofilm growth (over six days) for each PCR ribotype will be measured 
using 96-well microtitre plates assay. 
 
 The biofilm MIC (bMIC) and minimum biofilm eradication concentration 
(MBEC) for each PCR ribotype will be investigated using Calgary biofilm device 
(CBD) assay for metronidazole and vancomycin. 
 
 Viable count and spore count within biofilms for each PCR ribotype will be 
retrieved using 96-well microtitre plates (over six days) and CBD assay (over 
four days) 
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1.3. General Methods  
 
1.3.1. Preparation of C. difficile strains  
 
Human clinical Clostridium difficile strains of PCR ribotypes 078, 027 and 002, as 
well as, two control strains: E4 (PCR ribotype 010) and ATCC 700057 (VPI 11186) 
(PCR ribotype 038), were assessed in all studies. All clinical strains were isolated 
from the Leeds Teaching Hospitals NHS Trust and supplied courtesy of Professor 
Mark Wilcox, who retrieved them from multiple areas in the UK (Table 1.2). 
 
C. difficile strains were initially cultured on Brazier’s agar (CM0601, Oxoid, 
Basingstoke) supplemented with 5 mg/L lysozyme (62971-10G-F, Sigma-Aldrich, 
Gillingham) and 2% defibrinated horse blood (SR0050, Oxoid, Basingstoke), lysed 
with saponin (47036-50G-F, Sigma-Aldrich, Gillingham), which were incubated in 
an anaerobic cabinet at 37°C for two days. Once the colonies had grown, they 
were inoculated onto pre-reduced Columbia agar with 5% whole defibrinated 
horse blood and incubated in the anaerobic cabinet at 37°C for seven to 10 days 
for sporulation to occur. Once spores were produced they were harvested and 
mixed into a 50% ethanol 50% saline solution (~106 spores/ml). The solution was 
left at room temperature for an hour to kill any vegetative cells and leave the 
spores in solution; then the spore solution was then stored at 4°C (Freeman et 
al., 2003). 
 
When needed, 10-20 µl of spore solution was inoculated on Brazier’s agar (with 
supplements) for one to three days in an anaerobic cabinet at 37°C until the 
spores had germinated and grown into colony forming units (CFU). 
  
1.3.2. Statistical analysis  
 
All statistical analysis was conducted using IBM® SPSS® Statistics Version 22/23. 
Data were tested for normality using the ‘Explore tool’ and the Shapiro-Wilk test 
results were interpreted. If the data was normally distributed a one-way ANOVA 
test was conducted using the ‘one-way ANOVA tool’ or a two-way ANOVA test was 
conducted using the ‘Univariate tool’. If the results were not normally distributed 
a Kruskal-Wallis test was conducted using ‘K Independent Samples…’ tool. A 
significant difference was considered as a P-value of ≤0.05.   
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Table 1.1. C. difficile isolates used in this study, with PCR ribotype, year of 
isolation and location of isolation. 
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2. Comparing the Growth Rate and Cytotoxin 
Production Rate of Clostridium difficile PCR 
Ribotypes 078, 002 and 027 
 
 
2.1. Introduction 
 
There are four stages of bacterial growth in batch culture: lag phase, exponential 
phase, stationary phase and death phase. The duration of these phases may differ 
between microorganisms but the shape of the curve is likely to be similar. The lag 
phase is where there is no or little cell division, the exponential phase (also called 
the log or growth phase) is where cellular reproduction occurs, the stationary 
phase is where the growth rate and death rate are at equilibrium, and the death 
phase is where the death of cells exceeds cellular reproduction (Tortora et al., 
2004). Bacterial pathogens may express virulence factors at different stages 
within their growth cycle, indeed even bacteria of the same genus and/or species 
may be heterogeneous with respect to when toxins are released (Drummond et 
al., 2003a; Vohra and Poxton, 2011). Consequently, studies assessing 
heterogeneity of virulence factor expression between members of the same 
species are important in that they may help to elucidate differences between 
strains which may have an impact on the pathogenicity/virulence of the organism 
in vivo. 
       
Clostridium difficile is a mesophilic bacterium, therefore, this bacterium survives 
optimally in moderate-temperature environment and has been reported to have 
an optimum range of 30°C to 37°C (Karlsson et al., 2003; Rodriguez-Palacios et 
al., 2012; Tortora et al., 2004). As with all of the Clostridium species, C. difficile 
is able to sporulate in response to adverse environmental stimuli (nutrient 
limitation, detergents, or antibiotics, etc.). Indeed, temperature has been 
demonstrated to significantly affect C. difficile spore germination, with 
germination rate significantly higher at 37°C than at 20°C (Wheeldon et al., 
2008a). Kazamias and Sperry (1995) demonstrated the pH of the culture medium 
is important in determining C. difficile growth, which was optimal in an alkaline 
medium. Consequently, for an organism like C. difficile that inhabits the human 
colon (pH range 5.7-6.7) the optimal pH for growth may affect the site at which 
infection and subsequent disease occurs (Fallingborg, 1999).  
 
There are now over 600 PCR ribotypes of C. difficile, however only some are 
toxigenic and contains a 19.6KB pathogenicity locus (PaLoc), while non-toxigenic 
strains contain a non-coding 115-bp region (Braun et al., 1996; Fluit et al., 1991; 
Janezic et al., 2012; O'Connor et al., 2009). The PaLoc involves five genes, which 
produce, regulate or facilitate the release of toxins. The tcdA gene encodes toxin 
A (TcdA), the tcdB gene encodes toxin B (TcdB), the tcdR gene encodes a sigma 
factor that positivity regulates toxin production, the tcdC gene product putatively 
negatively regulates toxin production, and the tcdE gene product facilitates toxin 
A and toxin B release out of the cell. However, C. difficile also secretes its toxins 
when cell lysis occurs (Curry et al., 2007; Govind and Dupuy, 2012; Lyras et al., 
2009; Matamouros et al., 2007; O'Connor et al., 2009; Olling et al., 2012). The 
Spo0A gene is also involved in toxin productionn but is not part of the PaLoc 
(Underwood et al., 2009). TcdA and TcdB are the major virulence factors of C. 
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difficile and are both glycosylating toxins comprised of four domains: an activity 
(A) domain, a cutting (C) domain, a delivery (D) domain and a binding (B) domain 
(Carter et al., 2010; Curry et al., 2007; Shen, 2012). The toxins enter the host 
cell by binding to receptors on the cell surface and it is thought that TcdA and 
TcdB bind to different receptors, which subsequently triggers uptake of the toxins 
via endocytosis (Shen, 2012). Endosomal acidification then occurs which prompts 
the translocation of the A domain of the toxins into the cytosol which then binds 
to and glucosylates Rho GTPases. Consequently, the Rho GTP-GTD switching is 
disturbed which causes the actin cytoskeleton to disassemble, the cell to become 
rounded, and apoptosis to occur (Shen, 2012). These toxins are believed to have 
different functions in CDI, TcdA is thought to be involved more in intestinal 
damage whereas TcdB induces systemic intoxication and is thought to be more 
cytotoxic than toxin A (up to 1000-fold) (Aktories, 1997; Qa'Dan et al., 2000). 
Some strains only produce TcdB, these have both the toxin genes, within the 
PaLoc, however there is a 5.9 kb deletion within the 3’ end of the tcdA and tcdC 
genes, this prevents production of the TcdA protein (Drudy et al., 2007; Soehn et 
al., 1998). Strains which produce toxin B but not toxin A have been involved in 
case reports (Limaye et al., 2000) and in outbreaks worldwide (van den Berg et 
al., 2004). 
 
The tcdR gene, which encodes for the TcdR protein, positively regulates the 
production of the two toxins, is auto-activated by different environmental changes, 
such as temperature or culture medium, during the exponential phase of growth 
(Karlsson et al., 2003; Matamouros et al., 2007; O'Connor et al., 2009). 
Contrastingly, TcdC (encoded by the tcdC gene) putatively negatively regulates 
the production of the two toxins by interacting with the tcdR gene (Murray et al., 
2009). It is uncertain if TcdC does truly negativity regulate toxin production, 
however when bacterial growth enters stationary phase the expression of 
transcription of the tcdC gene stops, and toxin production increases (Matamouros 
et al., 2007). The tcdE gene encodes for the holin-like membrane protein, TcdE, 
which aids the secretion of toxin A and B out of the bacterial cell, however, unlike 
the tcdE gene in other bacteria, such as Escherichia coli, the C. difficile tcdE gene 
does not cause cell damage (Govind and Dupuy, 2012; O'Connor et al., 2009). 
Another locus which could also influence toxin production is the accessory gene 
regulator (agr) locus, which has been found in C. difficile PCR ribotypes, including 
PCR ribotype 027 (Carter et al., 2014; Martin et al., 2013; Stabler et al., 2009). 
AgrA was previously found to positively regulate the production of TcdA in PCR 
ribotype 027 strains (Darkoh et al., 2015; Martin et al., 2013).  
 
As well as being involved in sporulation, the Spo0A protein may also be involved 
in toxin regulation (Underwood et al., 2009). Underwood et al. (2009) found when 
the spo0A gene was inactivated when there was a reduction in toxin production. 
Whereas, Rosenbusch et al. (2012) concluded the Spo0A protein had a negative 
effect on toxin production. Both used the C. difficile 630Δerm strain, with the 
spo0A gene manipulated so it was active or inactive (or over active). Mackin et al. 
(2013) used a wild-type strains of PCR ribotype 027 (M7404 and R20291 strains) 
and strains with a mutated spo0A and, when observed, found an increase in toxin 
production (both toxin A and B) in the mutant strains. 
 
There are many variables which can affect cytotoxin production, for example: 
temperature, indeed Onderdonk et al. (1979) found, using a diploid human WI-38 
cells cytotoxin assay, that an increase in temperature from 37°C to 45°C elevated 
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cytotoxin production 1000-fold, however, Lei and Bochner (2013) compared C. 
difficile cytotoxin production between 22°C and 42°C, using a cytotoxin assay 
(using HT29, human lung adenocarcinoma (A549), Vero, and Chinese hamster 
ovary (CHO)-k1 cell lines), and observed that cytotoxin production was highest at 
37°C. Interestingly, this may be because the tcdR gene auto-activates at 37°C 
(Karlsson et al., 2003). Additionally, culture medium pH is another variable which 
may influence cytotoxin production. Onderdonk et al. (1979) demonstrated that a 
difference between pH 4 and pH 8 did not affect C. difficile cytotoxin production, 
however, Barth et al. (2001) reported that pH does influence the uptake of TcdB 
into cells. Barth et al. (2001) demonstrated that in pH 4.5 medium uptake of TcdB 
into CHO cells was greater when compared to a pH 7.5 medium.    
 
2.2. Aims and Objectives 
 
The aim of this experiment is to characterise and compare growth rate and 
cytotoxin production by C. difficile PCR ribotypes 078, 027 and 002.   
 
 This will be achieved by performing batch cultures of 11 C. difficile strains 
of each PCR ribotype and recording their growth profiles over a 48 hour 
period and also calculating maximum specific growth rates (µmax) between 
2 to 6 hours.  
 
 Toxin samples will be semi-quantified at 2 hour intervals over 72 hours 
using a Vero cell cytotoxicity assay.  
 
2.3. Materials and Methods 
 
2.3.1. C. difficile strains 
 
All strains were prepared using the methods stated in Section 1.2.1. 
 
The batch culture growth curves and µmax experiment (Section 2.3.3.) used all 11 
human clinical strains of each PCR ribotypes 078, 027 and 002 in triplicate.  
  
The Vero cell cytotoxicity assays (Section 2.3.4.) incorporated four human clinical 
strains of each PCR ribotypes 078, 027 and 002 in duplicate. 
 
2.3.2. C. difficile Batch Culture Preparation 
 
C. difficile colonies were swabbed from the Braziers agar plates into pre-reduced 
Brain Heart Infusion broth (CM1135, Oxoid, Basingstoke) supplemented with 
0.1% (w/v) L-cysteine hydrochloride (C1276-50G, Sigma-Aldrich, Gillingham) and 
0.5% (w/v) yeast extract (92144-500G-F, Sigma-Aldrich, Gillingham) (BHIS 
broth) (Dawson et al., 2012), and left to grow overnight in an anaerobic cabinet 
at 37°C. The overnight culture was inoculated into fresh BHIS, to give a 
standardised starting OD600 of 0.1. 
 
2.3.3. Preparation of Batch Culture Growth Curves and Maximum Specific 
Growth Rate Calculation 
  
Batch cultures were prepared using methods in Section 2.3.2. Samples were 
aseptically removed from each of the batch cultures, to record the OD600 at 2, 4, 
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5, 6, 24, 48 and 72 hours. To ensure accuracy, if the OD600 was above 0.700 the 
sample was diluted with sterile BHIS to ensure that readings fell within the linear 
range for the spectrophotometer (CE2021, Cecil, 2000 series) and the dilution 
factor accounted for when calculating the actual OD600. µmax (h-1) was calculated 
from the exponential phase (between 2 and 6 hours) of C. difficile growth by 
determining the gradient (trend line) of the biomass natural log (ln(biomass)) 
versus time (hours) plot in triplicate.  
 
2.3.4. Vero Cell Cytotoxicity Assay 
 
2.3.4.1. Preparation of Growth for C. difficile Cytotoxin Production 
 
To investigate the cytotoxin production profiles, C. difficile PCR ribotypes were 
prepared using methods in Section 2.3.2. The batch cultures were assayed at two 
hour intervals between 2 and 24 hours and the OD600 was also determined at each 
interval. Samples were also taken at 48 and 72 hours (from Section 2.3.3.). All 
cytotoxin samples were centrifuged (13000 rpm for 10 minutes) and the 
supernatants was removed and stored at 4°C for retrospective cytotoxin testing. 
All assays were performed in duplicate. 
 
2.3.4.2. Vero Cell Preparation  
 
Vero cells (84113001, African Green Monkey Kidney Cells, PHE culture collections) 
were retrieved from liquid nitrogen and slowly thawed out in 5% CO2 at 37°C. The 
thawed Vero cells were cultured in 25 cm3 flasks containing Dulbecco’s Modified 
Eagles Medium (D6546-Sigma-Aldrich, Gillingham), supplemented with 10% (v/v) 
new-born calf serum (N4637-Sigma-Aldrich, Gillingham), 1% (v/v) 
antibiotic/antimycotic solution (A5955, penicillin 100 U/ml, 100 mg/L 
streptomycin, 0.25 mg/L amphotericin, Sigma-Aldrich, Gillingham) and 1% (v/v) 
L-glutamine (G7513-Sigma-Aldrich, Gillingham) (DMEM) and incubated in 5% CO2 
at 37°C until a confluent monolayer was visible when examined under an inverted 
microscope (Olympus CKx41) (Figure 2.1.A). Once confluent, the Vero cell 
monolayer was passaged three times before use in the experiment in order that 
the optimal growth rate could be obtained (Ammerman et al., 2008).  
 
Passaging of Vero cells was conducted by removing DMEM from confluent 
monolayers and adding 0.5 ml  of Hanks Balanced Salt Solution (H9394-Sigma-
Aldrich, Gillingham) supplemented with 0.25 g/L trypsin-EDTA (T4174-Sigma-
Aldrich, Gillingham) (HBSS-trypsin-EDTA). HBSS-trypsin EDTA was agitated over 
the monolayer for 30 seconds to remove loosely adherent/dead cells, this was 
then discarded. A further 3 ml of HBSS-trypsin-EDTA solution was added to the 
25 cm3 flask and incubated in 5% CO2 for 10 minutes until the monolayer was no 
longer adherent. Trypsinised Vero cells were diluted into fresh supplemented 
DMEM such that the resultant cell concentration elicited a confluent monolayer 
after 24 hours (1:10 dilution) or 48 hours (1:20 dilution) and then were incubated 
in 5% CO2 at 37oC until confluent (Figure 2.1.A.). 
2.3.4.3. Preparation of Vero Cell Cytotoxicity Assay Microtitre Plates 
 
Trypsinised and diluted Vero cells were aliquoted into 96-well flat bottomed 
microtitre plates (FB56412, Fisher Scientific,) and incubated in 5% CO2 at 37°C 
until a confluent monolayer was visible under the inverted microscope (Figure 
2.1.A.). C. difficile culture supernatants were serially 10-fold diluted in sterile PBS 
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in 96-well microtitre plates (FB56412, Fisher Scientific,) to 10-5 and 20 μL was 
inoculated into each appropriate well of the microtitre plate (Figure 2.2.). 
Additionally, 20 µl of C. sordellii antitoxin (PL6508, Pro-Lab, Bromborough) was 
aliquoted into one well per dilution series (row B) which contained the undiluted 
C. difficile culture supernatant. Microtitre plates were then incubated in 5% CO2 
at 37oC for 24 and 48 hours and examined under the inverted microscope. A 
positive cytopathic effect (CPE) was determined in microtitre plate wells that 
demonstrated ≥50% Vero cell are rounding (Figure 2.1 B.). Cytotoxin titres were 
expressed as log10 relative units (RU) where rounding in the undiluted culture 
supernatant was scored 1 RU, rounding in the 10-1 dilution scored 2 RU etc.  
Neutralisation of the toxin by the C. sordellii antitoxin was required in order to 
confirm the specificity of the CPE. All assays were performed in triplicate, the 
median cytotoxin titre for each PCR ribotype was then calculated. 
 
2.3.5. Statistical Analysis 
 
For the cytotoxin assay results the Kruskal-Wallis statistical test was used. The 
Two-way ANOVA statistical test was used to analyse the difference between the 
growth for each PCR ribotype and time-point. The µmax results used a one-way 
ANOVA to test the significance. A P-value of ≤0.05 was considered statistically 
significant.   
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Figure 2.1. Vero cells were grown using supplemented Dulbecco’s 
Modified Eagles Medium (DMEM) then passaged using HBSS-trypsin-
EDTA; A) Confluent monolayer of Vero cells; B) Cytopathic effect 
caused when C. difficile toxin was added (observed at 100X 
magnification under an inverted microscope). 
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20 µl of each 
well
Neat
10-1
10-2
10-3
10-4
10-5
Control 
Neat 
2 ml trypsinised 
cells
18 ml DMEM
20 µl 
C. sordellii
antitoxin
180 µl row 
A,C-H
160 µl row B
  
Figure 2.2. Vero cell culture cytotoxicity assay for determining C. difficile cytotoxin 
titres. C. difficile toxin was diluted from a 10-fold dilution series into to Vero cells in 
a 96-well microtitre plate (after the Vero cells had grown in supplemented Dulbecco’s 
Modified Eagles Medium (DMEM)). A dilution with ≥50% cell rounding was classed as 
1 titre (relative unit, RU). C. sordellii antitoxin was added to row B to neutralise C. 
difficile cytopathic effect.   
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2.4. Results 
 
2.4.1. Batch Culture Growth Curves and Maximum Specific Growth Rate 
Calculation 
 
The µmax varied between the PCR ribotypes. PCR ribotype 002 had the highest 
mean µmax (0.73 h-1) whereas PCR ribotype 078 had the lowest (0.53 h-1). There 
was a significant difference between all three PCR ribotypes (PCR ribotype 027 
µmax: 0.64 h-1) (P≤0.001) (Appendix 1.2). The range of µmax of strains, within the 
PCR ribotype groups, overlapped (Appendix 1.5).  
 
Between 0-2 hours PCR ribotype 078 had a significant increase in biomass (0 
hours: 0.11 OD600, 2 hours: 0.31 OD600) (P≤0.001), whereas, PCR ribotype 027 
(0 hours: 0.09 OD600, 2 hours: 0.11 OD600) (P=0.15) and 002 (0 hours: 0.09 OD600, 
2 hours: 0.1 OD600) (P=0.15) were similar, this suggests that PCR ribotype 078 
has a shorter lag phase. The exponential phase (between 2 and 6 hours) showed 
PCR ribotype 078 had significantly higher average biomass readings at 6 hours 
(2.44 OD600) than PCR ribotype 027 (1.39 OD600) (P≤0.001) and 002 (2.10 OD600) 
(P≤0.001) (Figure 2.3.).  Between 8 and 12 hours could be defined as the death 
phase, as there was a dramatic decrease in biomass between these two time 
points for all three PCR ribotypes (Appendix 1.3). After 12 hours the OD600 
readings plateaued for PCR ribotype 078 (72 hours: 1.33 OD600), whereas PCR 
ribotype 027 gradually decreased between 12 to 72 hours (0.77 OD600) and PCR 
ribotype 002 plateaued between 12 to 24 hours (1.82 OD600) then decreased 
between 24 to 72 hours (1.08 OD600) (Appendix 1.3).     
 
It was observed that the overnight cultures for each PCR ribotype were variable 
in their OD600 readings. PCR ribotype 002 had noticeable higher overnight 
absorbance readings (average 2.17 OD600) than either PCR ribotype 027 (average 
1.79 OD600) and 078 (average 1.85 OD600) (results not shown). It was also 
observed, in BHIS medium, that PCR ribotype 078 showed more of a biomass 
pellet and the bottom of a culture tube than PCR ribotype 002 and 027 (Figure 
2.4). 
 
2.4.2. C. difficile Cytotoxin Production 
 
Some strains of PCR ribotype 078 started to produce detectable cytotoxin between 
2 and 24 hours, however most strains produced enough cytotoxin to induce some 
cell rounding (<50%) but not enough to elicit a titre of 1 RU (Appendix 1.5). At 
48 hours the cytotoxin titres of the PCR ribotype 078 group ranged between 1 to 
3 RU then increased to between 2 to 3 RU at 72 hour (Appendix 1.5). The PCR 
ribotype 027 group produced less than 1 RU of toxin between 2 to 10 hours, 
between 12 and 22 hours some strains produced 1 RU of toxin, then at 24 hours 
some strains produced more than 1 RU of toxin but not enough to be classed as 2 
RU (Appendix 1.3). At 48 hours all PCR ribotype 027 strains produced 1 RU of 
toxin then increased to producing 1 to 2 RU of toxin after 72 hours. None of the 
PCR ribotype 002 strains produced detectable cytotoxin before 24 hours, after 24 
hours of incubation some strains produced 1 RU, at 48 hours all strains produced 
1 RU of toxin, and at 72 hours all strains produced between 1 and 2 RU of toxin 
(Appendix 1.3. and Appendix 1.5).   
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At 24 hours, median cytotoxin titres did not differ significantly between PCR 
ribotype 078 and 027 (1 RU) (P=0.31). PCR ribotype 078 had the largest 
variability in cytotoxin titres at 24 hours (0 to 2 RU), whereas, PCR ribotype 027 
cytotoxin titres were all 1 RU at 48 hours PCR ribotype 078 median cytotoxin titres 
increased to 2 RU (range 1-3 RU), which was significantly higher than the median 
cytotoxin produced by PCR ribotype 027 and 002 (both: 1 RU) (P≤0.001).  
 
2.4.3. Comparison of Geographical Location 
 
The geographical location where each strain was isolated did not seem to correlate 
with growth rate or toxin production. PCR ribotype 078 showed little variation in 
µmax and toxin production for strains from different locations. The PCR ribotype 
027 isolates did have some variation, for example isolates from Bath (strains 19 
and 20) had an average µmax of 0.58 h-1 whereas the average µmax for Leeds 
isolates (strains 35 and 36) was 0.69 h-1 (Appendix 1.5.). However there was no 
variation in toxin production, all isolates at all-time points had 1 RU (Appendix 
1.5). Some PCR ribotype 002 isolates had similar results, for example the Leeds 
(strains 53 and 54) average µmax was 0.76 h-1 and the Harrogate (strains 66 and 
68) average was 0.75 h-1, whereas some showed µmax variation, for example the 
Cumberland (strains 39 and 40) average was 0.80 h-1 (Appendix 1.5). There was 
no variation between the locations for PCR ribotype 002 toxin production as all 
strains did not produce toxin at 2 hours and produce a titre of 1 RU at 24 and 72 
hours (Appendix 1.5). 
  
 
 
 
 
 
 
 
 
  
2
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Figure 2.3. Growth curves of C. difficile PCR ribotypes (RT) 078, 027, and 002 (mean optical density (OD)
600
 (±SE)) 
in supplemented Brain Heart Infusion broth over 6 hours in batch culture. 
  
*** statistically significant difference P-value ≤0.001 
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Figure 2.4. C. difficile PCR ribotypes cultured in supplemented Brain 
Heart Infusion broth broth overnight; A) PCR ribotype 078; B) PCR 
ribotype 027; C) PCR ribotype 002; D) blank broth. 
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2.5. Discussion and Conclusion 
 
Some PCR ribotypes of C. difficile are pathogenic and contain the PaLoc. This locus 
contains five genes, two of which are the tcdA and tcdB genes, which encode toxin 
A (TcdA) and toxin B (TcdB) (Janezic et al., 2012; O'Connor et al., 2009). These 
toxins are the major virulence factors of C. difficile, and some PCR ribotypes which 
produce more toxin, therefore cause more severe illness, are said to be 
hypervirulent (Curry et al., 2007; Goorhuis et al., 2008; Knetsch et al., 2011; 
Shen, 2012). Goorhuis et al. (2008) classified PCR ribotype 078 as hypervirulent 
after comparing clinical severity in patients infected with this PCR ribotype to 
severity observed in patients infected with PCR ribotype 027. However, this study 
did characterise virulence factors of PCR ribotype 078, for example cytotoxin 
production (Goorhuis et al., 2008; Janezic et al., 2012; PHE and CDRN, 2014; 
Shen, 2012). PCR ribotypes 078, 027, and 002 produce both TcdA and TcdB. The 
present study examined cytotoxin production (Section 2.2.4.) over 72 hours of 
four clinical isolates of C. difficile from each PCR ribotype using a Vero cell 
cytotoxicity assay (Appendix 1.3). Additionally, growth (for 11 strains per PCR 
ribotype) characteristics (Section 2.2.2.) over 48 hours were determined and 
compared between PCR ribotypes by assessing OD600 (Figure 2.3.). 
  
The growth curves and µmax varied of all three groups C. difficile PCR ribotypes 
throughout the experimental period of this study. The PCR ribotype 002 had the 
fastest µmax (0.73 h-1) compared to PCR ribotype 078 (0.53 h-1) and 027 (0.64 h-
1) (Appendix 1.2). These results are similar to Carlson Jr et al. (2013),who found 
that PCR ribotype 027 had a slower growth rate to other PCR ribotypes (such as 
PCR ribotype 014).  
 
Contrastingly, the observations of Moore et al. (2013) differed from the present 
study, for example, PCR ribotype 078 had lower absorbance readings than PCR 
ribotype 027 in Moore et al. (2013), however there was not a substantial difference 
between them both. Additionally, Moore et al. (2013) showed the growth curve of 
PCR ribotype 078 and 027 as having an exponential phase between approximately 
eight and 12 hours and a stationary phase between approximately 12 and 16 
hours, following which biomass readings decreased. Whereas, in the present study 
the results for PCR ribotype 078 and 027 suggested the exponential phase was 
between two and eight hours. After eight hours average OD600 of all three PCR 
ribotype groups decreased and there was no obvious stationary phase. These 
results may differ from Moore et al. (2013), who started the growth curve with 
1x103 C. difficile spores, whereas the present study diluted a vegetative cell 
culture, therefore growth had already started when the readings were taken. 
Similarly to the present study, Vohra and Poxton (2011) showed the exponential 
phase of PCR ribotype 027, between zero and eight hours, with no noticeable lag 
phase. The stationary phase was between eight and 16 hours then, after 16 hours, 
the C. difficile entered its death phase. These results may differ, to the present 
study, because Vohra and Poxton (2011) inoculated spores into anaerobic 
incubation medium and waited until the OD600 reached 1.0 before taking 
measurements to create the growth curves, the present study used BHIS medium 
to produce an overnight culture of vegetative cells, which was diluted to produce 
an OD600 of 0.1, therefore it is likely that the C. difficile, in Vohra and Poxton 
(2011), had already reached the exponential phase when the measurements were 
taken, whereas the growth in the present study may have been delayed. 
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The cytotoxin production profile (Section 2.2.4.) for the C. difficile PCR ribotype 
078 group differed to the profile of PCR ribotypes 027 and 002 assessed in this 
study. PCR ribotype 078 demonstrated increased cytotoxin production over the 72 
hour period in this study, which was also observed by Mackin et al. (2013), using 
a Vero cell cytotoxicity assay. Some strains of PCR ribotype 078 in the present 
study started demonstrate measureable cytotoxin at two hours, however this may 
be due to residual toxin from the overnight cultures when they were diluted 
(Appendix 1.5). Contrastingly, PCR ribotypes 027 and 002 cytotoxin titres were 
lower than PCR ribotype 078 at 48 and 72 hours, and titres increased over the 
experimental period. Warny et al. (2005) suggested that PCR ribotype 027 
produced quantitatively more toxins than a comparator group (toxinotype 0), 
however PCR ribotype 078 (toxinotype V) was not assessed. Vohra and Poxton 
(2011) used the C. difficile TOX A/B II kit to assess toxin production by PCR 
ribotype 027 over 24 hours. The authors observed substantially increased toxin 
production over 12 hours for PCR ribotype 027, and then a plateau between 12 
and 24 hours. Similarly, in the present study, PCR ribotype 027, cytotoxin was 
produced before 12 hours (albeit not enough to be classed as 1 RU of toxin), 
between 12 and 24 hours some of the strains did produce measurable toxin, 
however at 24 hours all strains produced cytotoxin above the 1 RU quantification 
limit. Some PCR ribotype 002 strains started to produce cytotoxin at 18 hours 
(less than 1 RU), and quantifiable levels at 24 hours, as the C. difficile biomass 
plateaued (Appendix 1.3.). This is consistent with Drummond et al. (2003b) who 
showed that strains from different virulent PCR ribotypes followed a similar 
pattern. However this study used different methods to the present study and only 
measured TcdA production using a toxin A ELISA. Median cytotoxin titres for PCR 
ribotype 002 strains were lower at 24 hours to those of PCR ribotypes 078 and 
027 and this may be due to the cells producing more toxin as there was not a 
significant difference between the OD600 of the three PCR ribotype groups. 
Similarly, at 48 hours the OD600 of PCR ribotype 078 and 002 were similar, whereas 
the OD600 for PCR ribotype 027 was lower. However, PCR ribotype 078 had higher 
toxin production than PCR ribotype 027; this may be due to there being more cells 
to produce the toxin. This could be the same at 72 hours as PCR ribotype 078 had 
the highest OD600 reading compared to PCR ribotype 002 and 027. PCR ribotype 
002 started to produce toxin at 48 hours as the OD600 reading decreased, this may 
be due to the higher number of cells dying and breaking down, as the bacterial 
lysis occurs the toxin stored within was released (Olling et al., 2012). These 
observations suggest that PCR ribotype 078 strains produce elevated levels of 
cytotoxin, even when compared to other strains which have been designated 
hypervirulent (PCR ribotype 027), which may potentially contribute to this PCR 
ribotypes reported hypervirulence (Goorhuis et al., 2008). 
 
There are other factors which could contribute to the reported elevated virulence 
of C. difficile PCR ribotypes 027 and 078. One such factor is a mutations within 
the tcdC gene, which negatively regulates cytotoxin production (Curry et al., 
2007; Matamouros et al., 2007). PCR ribotype 027 possesses a mutated version 
of this gene, which has an 18-bp deletion and a single base pair deletion in the 
117 position, resulting in a frame-shift in the gene which in turn produces a 
truncated TcdC protein (Curry et al., 2007; de Boer et al., 2010; Dupuy et al., 
2008; Murray et al., 2009). Carter et al. (2011) reported a wild-type of PCR 
ribotype 027 started to produce cytotoxin at 24 hours, slightly decreases at 48 
hours and then increases at 78 hour (Cartman et al., 2010). Carter et al. (2011) 
also reported when genetically modified PCR ribotype 027 had non-mutated 
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version of tcdC, cytotoxin production was dramatically decreased at all-time 
points, suggesting the mutated tcdC gene does contribute to the control of toxin 
production. Cartman et al. (2012) came to a different conclusion, the study 
compared wild-type R20291 (which has the deletion in the 117 frameshift and 
the 18-bp deletion) and wild-type C. difficile 630Δerm (PCR ribotypes 012) 
(which has an intact tcdC gene) with four strains of R20291 with different 
versions of the tcdC gene: 1) one with base-pairs 61 to 653 (out of 680) in the 
open reading frame (ORF) deleted to produce an in-frame deletion; 2) a strain 
with the single bp deletion in the 117 position repaired; 3) a strain with the 18-
bp deletion also repaired; and 4) a strain with the whole ORF replaced with the 
one in C. difficile 630Δerm, and two modified strains of C. difficile 630Δerm; 1) 
one with the base pair 61 to 672 (out of 699) deleted to create an in-frame 
deletion; and 2) another with a silent base pair in place of the in-frame deletion. 
The authors concluded there was no difference in cytotoxin production between 
these strains, regardless of tcdC status, therefore there is no link between the 
mutation in tcdC gene and toxin production in PCR ribotype 027 (Curry et al., 
2007; de Boer et al., 2010; Dupuy et al., 2008).  
 
PCR ribotype 078 also has a mutation in the tcdC gene however it is a 39-bp 
deletion, but to date there have been no studies done to determine how this TcdC 
variant modulates cytotoxin production (Cartman et al., 2010; Goorhuis et al., 
2008). The mutated tcdC of PCR ribotype 078 may potentially elicit less efficient 
negative regulation of C. difficile toxins than the comparative mutated tcdC of PCR 
ribotype 027, and therefore explain the elevated cytotoxin production observed in 
the present study. In order to prove this hypothesis, a similar study with PCR 
ribotype 078 which did not have a mutated tcdC would need to be performed. 
 
In conclusion, the results of the present study contribute to our knowledge about 
factors that might enhance the apparent hypervirulent status of PCR ribotype 078. 
This is due to its increased toxin production compared to the hypervirulent PCR 
ribotype 027 and the virulent PCR ribotype 002. PCR ribotype 078 was also shown 
to produce increased peak biomass when compared to PCR ribotype 027 and 002 
over an 8 hour period, but growth curves with additional time points after 8 hours 
would need to be performed in order to assess the reproducibility of these findings 
and also determine if comparator ribotypes reached the same peak biomass at a 
period between 8 and 24 hours (Appendix 1.3). Elevated cytotoxin production 
titres and also cytotoxin production earlier in the growth cycle could contribute to 
the virulence of C. difficile PCR ribotype 078 and elicit more severe disease in 
patients. The elevated µmax of C. difficile PCR ribotype 002 in comparison to the 
reported hypervirulent ribotypes is interesting and warrants further study, 
especially since PCR ribotype 002 is now one of the most commonly isolated 
ribotypes in the UK (Prof. Mark Wilcox – personal communication). 
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3. Comparing Minimum Inhibitory 
Concentrations of Clostridium difficile PCR 
Ribotypes 078, 027 and 002 
 
3.1. Introduction 
 
Antimicrobial susceptibility testing is performed to characterise bacterial (and 
fungal) pathogens in vitro, to determine which antimicrobials (and concentrations) 
could possibly help treat bacterial infections in vivo. Indeed, susceptibility testing 
can also be used to see if antimicrobial resistance has evolved in bacteria which 
cause disease (Kahlmeter et al., 2003). This study determined the MIC of eight 
antimicrobials against three C. difficile PCR ribotypes using an agar incorporation 
method (AIM). 
 
Antibiotic properties of organisms have been known about since the Roman and 
Egyptian eras, as shown by traces of antibiotics found in skeletons from those eras 
(Aminov, 2010). Even though penicillin is widely thought to be the first antibiotic 
discovered by Alexander Fleming in 1929, by observing a fungus which “most 
closely resembles [Penicillium] rubrum”, antibiosis was being observed before this 
discovery was made (Aminov, 2010; Fleming, 1929). William Roberts, in 1874, 
noticed Penicillium glaucum was not contaminated with bacteria easily. 
Correspondingly, this was later supported by John Tyndall, who noted that a 
measurement of broth rarely contained both bacteria and fungi at the same time 
(Wheat, 2001). Since then microbiologists, such as Fleming, Schmith and 
Reymann, developed the methods to determine the susceptibly of the organisms 
to these antimicrobial agents (Fleming, 1929; Wheat, 2001). Fleming (1929) was 
one of the first to use methods to determine MICs (although the term was not 
used), using broths containing different concentrations of penicillin and observing 
how it affected the growth of bacteria, such as Haemophilus influenzae (formerly 
Bacillus influenzae). In the 1940’s Schmith and Reymann expanded the methods 
by incorporating sulphapyridine into agar to find the MIC of gonococci (Wheat, 
2001). Subsequently, in the 1960s WHO published a report to standardise these 
methods. At present, in European organisations such as The British Society for 
Antimicrobial Chemotherapy (BSAC) and The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), have standardised different 
methods, however in 2016 BSAC will support the EUCAST method to acquiring 
breakpoints (BSAC, 2015; Wheat, 2001). Methods for assessing susceptibility to 
antimicrobial agents include: ellipsoidal methods (including E-test), disc diffusion 
testing, broth MIC testing, and AIM. All of these methods have their own 
advantages: E- testing is easier to use than AIM but may not detect reduced 
susceptibility to some antimicrobial agents, for example metronidazole, AIM can 
concurrently test multiple bacteria and identifies the MIC endpoints, disc diffusion 
methods can be used as a screening test and can be modified easily (Baines et 
al., 2008; OIE, 2012; Varela et al., 2008). There may be variability in antimicrobial 
susceptibility results regardless of the method employed whether in the clinical or 
research settings.  For example, Baines et al. (2008) compared the MICs acquired 
from E-testing and AIM and found C. difficile isolates had a geometric mean MIC 
for metronidazole of 9.19 mg/L using AIM and 3.12 mg/L using E-testing (both 
using Wilkins Chalgren base agar); therefore AIM produce higher results than E-
testing (Baines et al., 2008; OIE, 2012). Triple-stage chemostat gut models are 
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used to replicate the environment within the gut, therefore, it is a good in vitro 
indicator of how C. difficile is affected by the incorporation of the antibiotics in a 
gut environment (in vivo) (Baines et al., 2009; Macfarlane et al., 1998). These 
methods have been used to study antimicrobial resistance in the gut microflora 
and C. difficile. Other methods have been developed to find genetic mechanisms 
of resistance. One of the advantages of using the genetic methods, such as PCR, 
is that they can be faster in the detection of resistance markers, so can be used 
to find an appropriate treatment for emergency cases (Courvalin, 1991). 
 
It is common practice to use antimicrobial breakpoints to determine the 
susceptibility of bacteria to antimicrobials (Angeby et al., 2012; Jorgensen and 
Ferraro, 2009). Committees, such as BSAC, EUCAST and the Clinical and 
Laboratory Standards Institute (CLSI), define these breakpoints (Angeby et al., 
2012; BSAC, 2013; CLSI, 2007; EUCAST, 2014; Kahlmeter, 2014). One of the 
factors which go towards determining the breakpoint is to find the Epidemiological 
cut-off (ECOFF) values which are determined by compiling the MICs of wild-type 
strains (defined as strains with no resistance mechanisms (mutational or 
phenotypically detectible)) from many different sources (Angeby et al., 2012; 
Kahlmeter, 2014). The data collected goes towards the production of three 
antimicrobial susceptibility classifications: resistant, intermediate and susceptible. 
If a strain is deemed resistant to an antibiotic, it is unlikely to be inhibited by a 
dosage normally given in a clinical setting. An antibiotic-susceptible strain is highly 
likely to be treated with normal dosage use, whereas, with a strain of intermediate 
susceptibility it is unclear how successfully the normal dosage of antibiotic will 
affect the strain (Angeby et al., 2012; Jorgensen and Ferraro, 2009). The 
disadvantage of using breakpoints is that there is debate of how reliable they are, 
for example BSAC breakpoints corresponds to the concentrations of antibiotics 
within the blood, whereas, European committees set their breakpoints lower than 
the breakpoints set by BSAC (Phillips, 2001). There is a difference of breakpoints 
around the world, for example, Ferraro (2001) reports there is an eight-fold 
difference between the MIC breakpoints for cefotaxime and ceftazidime used in 
USA (≤8 mg/L for both antibiotics) and UK (≤1 mg/L for both antibiotics), this 
could be the result of varying dosages and methods.  
 
CDI can be contracted by a patient taking antibiotics, which inhibit other bacteria 
within the gut, allowing C. difficile to thrive (Nelson et al., 2011). However, not all 
antibiotics cause CDI. Studies have been conducted to see which antibiotics maybe 
suitable for treatment of CDI. For example, in a clinical setting metronidazole and 
vancomycin are already used as antibiotic treatments for different severities of 
CDI (Al-Nassir et al., 2008; Freeman et al., 2007). 
 
Metronidazole, a nitroimidazole compound, has been a major treatment for 
anaerobic bacterial infections, including C. difficile infection, since the 1960s 
(Edwards, 1993; Freeman et al., 1997; Menendez et al., 2002). Metronidazole 
inhibits bacterial DNA synthesis, to do this, first the compound has to become 
reduced within the cell. The reduced form of metronidazole oxidises DNA and 
results in the breakage of the DNA strands and ultimately death of the cell 
(Edwards, 1993; Menendez et al., 2002; Sigeti et al., 1983). Reduced 
susceptibility to metronidazole has been shown in strains of C. difficile including 
some strains of PCR ribotype 027, although the mechanism(s) of this reduced 
susceptibility remain to be determined (Chong et al., 2014). This may be due to 
a group of nitroimidazole reductase (nim) genes, which has been found in a range 
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of anaerobic bacteria, such as Bacteroides fragilis. The nim gene product reduces 
nitrates left behind from the antibiotics into amino acids which are non-toxic to 
bacterial DNA (Chong et al., 2014; Dubreuil and Odou, 2010). Additionally, some 
strains of C. difficile have been found to produce the RecA protein after 
metronidazole treatment, which aids in the repairing of DNA (Chong et al., 2014). 
Other resistance mechanisms could involve mutations within the ferric uptake 
regulator (fur) gene and oxygen-independent coproporphyrinogen III oxidase 
(hemN) gene, which have been found in the genome of PCR ribotype 027 (Lynch 
et al., 2013; Moura et al., 2014). Lynch et al. (2013) found that some 
metronidazole resistant strains of C. difficile have mutations in the fur and hemN 
genes. 
 
Vancomycin is used to treat more severe cases of CDI (Al-Nassir et al., 2008). 
This antibiotic was discovered in 1953 as a glycopeptide compound produced by 
Amycolatopsis orientalis and 5 years later it started to be used to treat Gram-
positive bacterial infections. Subsequently, in 1978 vancomycin was used to treat 
CDI (Freeman et al., 2010; Heinlen and Ballard, 2010; Losey et al., 2001; 
Nagarajan, 1991; Yim et al., 2014). Vancomycin, like other glycopeptide 
antibiotics, binds to the terminal D-ala-D-ala residues of new peptidoglycan and 
its precursor lipid II within the bacterial cell wall. This inhibits peptidoglycan 
synthesis by isolating the substrate within D,D-transpeptidases which bonds 
peptidoglycan strands together (Nagarajan, 1991; Yim et al., 2014). Vancomycin 
also separates the substrates from the enzyme transglycosylases, which transfers 
a pentapeptide subunit from the lipid II precursor to the cell wall. These two 
processes weaken the cell wall, affect cell division and results in cell death (Yim 
et al., 2014). Vancomycin resistance was reported in C. difficile in Poland in 1991 
and reduced susceptibility has been found to develop in some strains (in vitro) 
(Leeds et al., 2013; Owens et al., 2008). This may be due to a substitution of 
proline and the addition of leucine in the MurG protein, which is involved in 
peptidoglycan synthesis (Leeds et al., 2013). Other Gram-positive bacterial 
species such as Enterococcus spp. have a range of van genes which produce 
peptidoglycan precursors with the reduced ability to bind to glycopeptide 
antibiotics (Chen et al., 2013). 
 
Two antibiotics which are part of the fluoroquinolone class are ciprofloxacin and 
moxifloxacin. This group of antibiotics are active against both Gram-negative and 
Gram-positive bacteria by targeting two enzymes involved in DNA replication 
(Goswami et al., 2006; Hooper, 2000). DNA gyrase is usually targeted in Gram-
negative bacteria, the enzyme catalyses the negative supercoiling of DNA, from 
positively supercoiled DNA to relaxed DNA, then relaxed DNA to negatively 
supercoiled DNA. Topoisomerase IV is typically targeted in Gram-positive bacteria, 
this enzyme also catalyses positively supercoiled DNA into relaxed DNA but can 
also separate linked daughter chromosomes after DNA replication (Collin et al., 
2011; Drlica and Zhao, 1997; Hooper, 2000; Rafii et al., 2005; Redgrave et al., 
2014; Sriram et al., 2006). Both enzymes have to bind to the DNA to break the 
strand so the DNA can be relaxed and unlinked, then joined back together during 
replication. Fluoroquinolones modify the topoisomerase enzymes so the release of 
the DNA is inhibited (Redgrave et al., 2014). Ciprofloxacin has a second function 
in Gram-positive bacteria, the antibiotic forms ROS by breaking down the iron 
regulatory dynamics inside the bacteria and this results in cell death (Goswami et 
al., 2006; Kohanski et al., 2007). Resistance to fluoroquinolones in C. difficile has 
been associated with mutations within a region of DNA known as the quinolone 
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resistance-determining region (QRDR), which contains gyrA and gyrB (which 
encode for DNA gyrase). This region also contains pseudoautosomal (par) C and 
parE (encodes of topoisomerase IV) in other bacteria, such as E. coli, however C. 
difficile does not have these genes. This region inhibits the modification of the 
enzymes by the fluoroquinolones (Dridi et al., 2002; Redgrave et al., 2014; 
Rodriguez et al., 2014; Solomon et al., 2011). Both moxifloxacin and ciprofloxacin 
have been associated with increased risk of potentiating CDI (Borgmann et al., 
2010; O'Connor et al., 2004). 
 
Bacterial ribosomes are targeted by many antibiotics as they are the main 
structures in bacterial protein synthesis (Lambert, 2012). The ribosome consists 
of two subunits, 30S and 50S, to create a 70S structure. Each subunit has two 
sites: the 30S has aminoacyl-tRNA (A) site and peptidyl-tRNA (P) site, 50S has 
exit (E) site and P site. These sites help with the binding of tRNA and translocation 
in the ribosome (Fischer et al., 2010; Selmer et al., 2006). The 30S subunit joins 
to mRNA, fmet-tRNA, tRNA, methionine, GTP and three initiation factors (IF 1 to 
3) to form the initiation complex, this joins to the 50S subunit, to initiate protein 
synthesis (Bozdogan and Appelbaum, 2004). 
 
Linezolid is an oxazolidinone antibiotic which is used to treat Gram-positive 
bacterial infections. However, this antimicrobial agent is not currently used to treat 
C. difficile infections (Baines et al., 2011). Linezolid binds to the 50S subunit within 
the bacterial ribosome, blocking the initiation complex from binding to the 50S 
subunit. Linezolid is also thought to prevent the formation of the initiation 
complex, which hinders the development of the 70S complex, therefore, inhibiting 
proteins synthesis (Bozdogan and Appelbaum, 2004; Diep et al., 2012). Linezolid 
is used to treat infections where the bacteria are resistant to other antibiotics, 
such as infections caused by methicillin-resistant Staphylococcus aureus (MRSA) 
(Pelaez et al., 2002). Pelaez et al. (2002) found linezolid was active against C. 
difficile strains which were resistant to metronidazole or had reduced susceptibility 
to vancomycin in vitro. Resistance to linezolid is rare, despite this, resistance has 
been found to occur in some strains of C. difficile (Ager and Gould, 2012; Baines 
et al., 2011). In other Gram-positive bacteria, such as S. aureus, resistance has 
been found to occur due to a mutation within the drug target site of the 23S rRNA, 
part of the 50S subunit, which could be caused by a multidrug resistance (MDR) 
gene known as the chloramphenicol-florfenicol resistance (cfr) gene. The cfr gene 
encodes for an addition of a methyl group to the 23S rRNA which affects the 
binding of the antibiotics to the site (Ager and Gould, 2012; Chen et al., 2013; 
Long et al., 2006; Morales et al., 2010; Steitz et al., 2012). 
 
Tetracycline, part of the tetracycline family, is a broad spectrum antibiotic which 
is produced naturally by Streptomyces aureofaciens, S. rimosus, and S. 
viridofaciens. This antibiotic is used to treat infections of both Gram-positive and 
Gram-negative bacteria (Chopra and Roberts, 2001; Thaker et al., 2010). This 
antibiotic is a group one tetracycline antibiotic, which means it has lower 
absorption than other tetracyclines within the body and is administered orally. 
Between 20 and 60% of the administered tetracycline is excreted in faeces, since 
tetracyclines can be absorbed by the stomach and duodenum before passing into 
the colon. This suggests only a small percentage of the antibiotic would get to the 
colon to be effective against the C. difficile (Agwuh and MacGowan, 2006). Like 
linezolid, tetracycline also binds to and inhibits the bacterial ribosome. However, 
tetracycline binds to the 30S subunit so the A site cannot bind to it, this inhibits 
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protein syntheses (Chopra, 2002; Griffin et al., 2011; Thaker et al., 2010). 
Tetracycline resistance in bacteria may be encoded by a range of genes designated 
tet, for example tetL and tetM. The tetL gene encodes for a membrane-bound 
efflux protein, which transport tetracycline out of the cell (Chopra and Roberts, 
2001). The tetM gene encodes for a cytoplasmic ribosome protection protein, 
TetM, which binds to the A site of the ribosome to inhibit the binding of tetracycline 
(Burdett, 1996; Chopra and Roberts, 2001). Even through, tetracycline is a broad 
spectrum antibiotic it has been shown to have a low risk of causing CDI (Brown et 
al., 2013).  
 
Erythromycin and clindamycin are two antibiotics which are active via a similar 
mechanism. Erythromycin was discovered in 1952 as a product of Streptomyces 
erythreus and was classified as a member of the macrolide family (Mazzei et al., 
1993). Clindamycin is a lincosamide antibiotic, which is a derivative of a naturally 
occurring antibiotic produced by S. lincolnensis, known as lincomycin (Kulczycka-
Mierzejewska et al., 2012). Clindamycin is usually used to treat Gram-negative 
bacteria because it has high solubility in lipids, this allows it to penetrate through 
the lipid membrane of the bacteria. However, erythromycin is active against some 
Gram-positive and some Gram-negative bacteria, although it is unable to pass 
through the cell wall of some Gram-negative Bacilli (Douthwaite, 1992; Peters et 
al., 1992; Tortora et al., 2004). Both antibiotics bind within the nascent peptide 
exit tunnel, part of the 50S subunit, this dislocates peptidyl-tRNAs from the 
ribosome and blocks proteins which are produced by the ribosome (Gamerdinger 
and Deuerling, 2012; Tenson et al., 2003). Erythromycin and clindamycin 
resistance is encoded by a range of erm genes, one in particular is the ermB gene. 
These genes add methyl groups to the 23S rRNA within the 50S subunit, inhibiting 
the binding of the erythromycin or clindamycin (Palmieri et al., 2013; Rose et al., 
2012; Solomon et al., 2011). Another range of genes, known as the macrolide 
efflux (mef) genes, are also associated with erythromycin resistance in Clostridium 
species, such as C. perfringens. This gene encodes for a membrane-bound efflux 
pump, which activity removes erythromycin from the bacterial cell (Leclercq, 
2002; Poole, 2005; Soge et al., 2009). Both the ermB and the mefA have been 
linked to transposons which can pass the genes to C. difficile strains, therefore it 
is possible for these genes to be part of the C. difficile genome (Soge et al., 2009).  
 
Antibiotic resistance in bacteria is an increasing problem worldwide which may 
soon make antibiotics obsolete (WHO, 2014). C. difficile PCR ribotypes have 
acquired resistance to some antibiotics, which has resulted in outbreaks across 
the world (McDonald et al., 2005). Resistance to fluoroquinolones has developed 
in PCR ribotypes including 002, 027 and 078, and has been linked to CDI outbreaks 
caused by these PCR ribotypes (Goorhuis et al., 2008; Solomon et al., 2011; 
Vardakas et al., 2012). For example, Borgmann et al. (2010) found a correlation 
between the increase of ciprofloxacin prescriptions and incidents of CDI. McDonald 
et al. (2005) found the development of fluoroquinolone resistance in PCR ribotype 
027 isolates was connected to outbreaks in the USA. Resistance to 
fluoroquinolones, in animal isolates of PCR ribotype 078, has also resulted in a 
spread of PCR ribotype 078 in pig farms (Keessen et al., 2013). Wiuff et al. (2011) 
found out of 101 PCR ribotype 002 isolates in Scotland only 1% were resistant to 
moxifloxacin. Clindamycin resistance also varies between different PCR ribotypes. 
Indeed, Tenover et al. (2012) found different PCR ribotypes isolates in North 
America with varying resistance to clindamycin. The study found 71.4% of PCR 
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ribotype 078 isolates, 47.5% of PCR ribotype 027 and 5.9% of PCR ribotype 002 
were resistant to clindamycin (Tenover et al., 2012).  
 
3.2. Aim and Objective 
 
To compare susceptibilities of C. difficile PCR ribotype groups 078, 027, and 002 
to a range of antimicrobial agents. 
 
 An Agar Incorporation Method (AIM) will be used to determine the MICs of 
eight antimicrobial agents against C. difficile PCR ribotypes 078, 027 and 
002. 
 
3.3. Materials and Methods 
 
3.3.1. C. difficile strains 
 
This experiment used 11 human clinical strains of C. difficile PCR ribotypes 078, 
027 and 002, along with an internal control strain, E4 (PCR ribotype 010), and 
ATCC 700057 (VPI 11186) (PCR ribotype 038). The strains were prepared using 
methods in Section 1.2.1. 
 
3.3.2. MIC Testing using Agar Incorporation Methods 
 
AIM was used to determine the MIC of the eight antibiotics, the methods used 
were based on methods in O'Connor et al. (2008) and Freeman and Wilcox (2001). 
The antibiotics compared were: metronidazole (M3761-25G, Sigma-Aldrich, 
Gillingham), vancomycin hydrochloride (V2002-1G, Sigma-Aldrich, Gillingham), 
linezolid (PF-00184033, Pfizer, Surrey), erythromycin (E6376-25G, Sigma-
Aldrich, Gillingham), tetracycline hydrochloride (T3383-25G, Sigma-Aldrich, 
Gillingham), clindamycin hydrochloride (PF-00344619-01, Pfizer, Surrey), 
moxifloxacin (06669292-SV0001HC, Bayer, Berkshire) and ciprofloxacin 
(11939800-SV00019P, Bayer, Berkshire). 
 
A spore suspension of each C. difficile strain was inoculated onto supplemented 
Brazier's agar plates and placed into an anaerobic cabinet at 37°C for 24 hours. 
Four to five well-separated C. difficile CFUs were inoculated into 5 ml of pre-
reduced Schaedler's anaerobic broth (CM0497, Oxoid, Basingstoke) and incubated 
in the anaerobic cabinet at 37°C overnight. Wilkins-Chalgren anaerobe agar 
(CM0619, Oxoid, Basingstoke) was made (to the manufacturer’s instructions) for 
each concentration of antibiotic and two for control plates, then placed in an 
autoclave. A 2560 mg/L stock solution was made for each antibiotic, dissolved in 
distilled water (for erythromycin ethanol was used). The stock solution was then 
sterilised using a 0.22 µm syringe filter. The stock was used to make a 2-fold 
dilution series in sterilised distilled water (Table 3.1). Each dilution was mixed into 
a bottle of molten Wilkins-Chalgren agar (50oC) and poured into sterile Petri 
dishes. 
 
The agar was left to solidify and then dried in a microbiological safety cabinet for 
approximately 10 minutes. Each culture was diluted 1:10 in sterile pre-reduced 
saline solution in a sterile multipoint inoculator (Mast Uri™ Dot, Mast Diagnostics) 
block, so there was approximately 1x104 CFU/spot. Each plate was inoculated 
using 1 µL/spot pins, making sure to inoculate one of the anaerobic and aerobic 
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controls at the start and at the end. In between each set of antibiotics the pins 
were dipped in ethanol and then flamed. The inoculated agar plates were 
incubated overnight at 37°C in the appropriate atmosphere. The plates were read 
and the MIC endpoint was determined as the lowest concentration of antimicrobial 
where a marked change in growth when compared to the control plates was 
observed.  
 
Geometric mean MIC values were calculated using the ‘geomean’ function in 
Microsoft Office Excel 2013, to show variations between the different PCR 
ribotypes and antibiotics which may not be seen using the MIC50, MIC90 and range 
(Davies, 1990). The MIC50 and MIC90 are the concentrations which will inhibit 50% 
and 90% of the bacteria isolates respectively, and were calculated by ordering the 
MICs in numerical order then using the equations from Schwarz et al. (2010) 
(below) to find the position of the value used for the MIC50 and MIC90: 
 
If number of strains (n) is an odd number then the MIC50 is the MIC at position X 
in the ordered MIC list, where X = number of strains (n + 1) x 0.5 
 
If n is an even number, then X = n x 0.5. 
 
For MIC90, X = n x 0.9 (next whole number) etc. 
 
3.3.3. Breakpoints 
 
The breakpoints for each antimicrobial agent are shown on Table 3.2. These 
breakpoints were created by CLSI (2007) which determined breakpoints using the 
agar dilution method, BSAC (2013) which used disc diffusion method to determine 
the breakpoints (as C. difficile breakpoints were not presented the breakpoints for 
Staphylococci were used) and EUCAST (2014) which used breakpoints based on 
ECOFF values. 
 
3.3.4. Statistical Analysis 
 
The Kruskal-Wallis statistical test was used to assess the statistical significance of 
differences in MICs between C. difficile strains. A noticeable difference was classed 
as a more than one doubling dilution difference between MICs.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. The volumes of distilled water and antibiotic used to produce 10-
fold dilutions for each antibiotic used in order to produce the desired 
concentrations of antimicrobials that were incorporated into Wilkins Chalgren 
agar plates. 
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Table 3.2. Breakpoints used to determine if the C. difficile strain are 
resistant (R), susceptible (S) or in the intermediate range (I) for 
metronidazole (Met.), vancomycin (Van.), ciprofloxacin (Cip.), 
clindamycin (Clind.), erythromycin (Ery.), linezolid (Lin.), moxifloxacin 
(Mox.) and tetracycline (Tet.). These breakpoints were produced by CLSI 
(2007) which used the agar dilution method to determine the breakpoints, 
EUCAST (2014) which based the breakpoints on epidemiological cut-off 
values and BSAC (2013) which used disc diffusion method to determine 
the breakpoints (as C. difficile breakpoints were not presented the 
breakpoints for Staphylococci were used).    
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3.4. Results 
 
3.4.1. Antimicrobial Susceptibilities: Comparison between PCR Ribotypes 
 
The metronidazole geometric mean MIC for the PCR ribotype 078 group was 0.08 
mg/L which was significantly less than the corresponding geometric mean MIC for 
PCR ribotype 002 strains (0.18 mg/L) (P≤0.01) and 027 (1.37 mg/L) (P≤0.001) 
strains. The PCR ribotype 027 groups metronidazole geometric mean MIC was 
significantly greater than that of PCR ribotype 002 group (P≤0.001) (Table 3.3.). 
The MIC50 for PCR ribotype 078 isolates was the lowest (0.125 mg/L) compared 
to that of the PCR ribotype 027 group (2 mg/L) and PCR ribotype 002 group (0.25 
mg/L). The MIC90 for PCR ribotype 078 isolates (0.125 mg/L) was lower than PCR 
ribotype 002 strains (0.25 mg/L) and there was a marked difference between 
them and the MIC90 of PCR ribotype 027 group (4 mg/L). All the strains for each 
PCR ribotype were susceptible to metronidazole using breakpoints but isolates 
with MICs ≥2mg/L were above the ECOFF (Figure 3.1. and Appendix 1.5).  
 
The vancomycin results (Table 3.3.) indicated that the geometric mean MICs were 
not significantly different. There were no substantial differences between 
vancomycin MIC50 (all were 0.5 mg/L) and MIC90 (the PCR ribotype 078 strains 
were 1 mg/L and the PCR ribotype 002 and 027 groups were both 0.5 mg/L). All 
the strains for each PCR ribotype were susceptible to vancomycin (Figure 3.1. and 
Appendix 1.5). 
 
The ciprofloxacin geometric mean MICs were significantly lower  for PCR ribotype 
078 isolates (7.51 mg/L) compared to the PCR ribotype 027 group  (68.16 mg/L) 
(P≤0.001) and the PCR ribotype 002 group (10.29 mg/ml ) (P≤0.05). The 
difference between PCR ribotype 027 and 002 geometric mean MICs for 
ciprofloxacin were also statistically significant (P≤0.001). The ciprofloxacin MIC50 
for each PCR ribotype were the same (8 mg/L) and MIC90 results for the PCR 
ribotype 078 strains (8 mg/L) were noticeably lower than the MIC90 for the PCR 
ribotype 027 isolates (>128 mg/L), but there was no marked differences between 
the PCR ribotype 078 and 002 groups (16 mg/L). All the strains for all the PCR 
ribotypes were resistant to ciprofloxacin (Figure 3.1. and Appendix 1.5). 
 
The clindamycin results (Table 3.3.) showed PCR ribotype 002 had the significantly 
highest geometric mean MIC (3.31 mg/L) compared to PCR ribotype 027 (0.44 
mg/L) (P≤0.001) and 078 (0.09 mg/L) (P≤0.001), and the highest MIC50 and 
MIC90 (both 8 mg/L). PCR ribotype 078 had the lowest geometric mean MIC (0.09 
mg/L) (PCR ribotype 027: P≤0.01) and the lowest MIC50 (0.06 mg/L) and MIC90 
(0.25 mg/L). The geometric mean for PCR ribotype 027 was 0.44 mg/L, the MIC50 
and MIC90 were 0.5 mg/L. All PCR ribotype 078 and 027 strains were susceptible 
to clindamycin, whereas 64% of the PCR ribotype 002 strains were (Figure 3.1. 
and Appendix 1.5).  
 
The geometric mean MIC results for erythromycin MIC for the PCR ribotype 027 
group (128 mg/L) were significantly higher than PCR ribotype 078 (P≤0.001) and 
PCR ribotype 002 (P≤0.001). The MIC50 of the PCR ribotype 027 group was also 
128 mg/L and the MIC90 was ≥128 mg/L. The geometric mean MICs for the PCR 
ribotype 078 and 002 groups were similar (P=0.07). All the strains for PCR 
ribotype 027 and 9% of strains of PCR ribotype 078 were resistant to 
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erythromycin, All PCR ribotype 002 strains and 91% of the PCR ribotype 078 
strains were susceptible (Figure 3.1. and Appendix 1.5).  
 
The geometric mean MIC for linezolid (Table 3.3.) for the PCR ribotype 078 group 
(0.73 mg/L) was significantly higher than the PCR ribotype 027 group (0.25 mg/L)  
(P≤0.01) but was similar to the PCR ribotype 002 group (0.5 mg/L) (P=0.25). The 
PCR ribotype 027 group geometric mean MIC was significantly lower than PCR 
ribotype 002 group geometric mean (P≤0.05). There was a marked difference 
between the MIC50 of the PCR ribotype 078 group (1 mg/L) and the PCR ribotype 
027 isolates (0.25 mg/L) however there was not a marked difference between the 
PCR ribotype 002 strains (0.5 mg/L) and the other PCR ribotypes. There was a 
marked difference between the MIC90 for the PCR ribotype 078 strains (2 mg/L) 
and the MIC90 for the PCR ribotype 027 group (0.5 mg/L). All the strains from all 
PCR ribotypes were susceptible to linezolid (Figure 3.1. and Appendix 1.5). 
 
The results for moxifloxacin (Table 3.3.) showed that the geometric mean MIC for 
the PCR ribotype 078 group was 1.07 mg/L, which was significantly lower than the 
geometric mean for the PCR ribotype 027 group (32 mg/L) (P≤0.001) and PCR 
ribotype 002 isolates (1.76 mg/L) (P≤0.01). The results for PCR ribotype 027 and 
002 were also significantly different (P≤0.001). The MIC50 results were the same 
as the MIC90 results for each PCR ribotype. The MIC50 and MIC90 for the PCR 
ribotype 027 strains (32 mg/L) were the highest, whereas, there was no noticeable 
difference between the MIC50 and MIC90 results for the PCR ribotype 078 (1 mg/L) 
and 002 (2 mg/L) groups.  All the PCR ribotype 002 strains and 91% of the PCR 
ribotype 078 were susceptible to moxifloxacin, 9% of the PCR ribotype 078 and 
all the PCR ribotype 027 strains were resistant (Figure 3.1. and Appendix 1.5).  
 
The results for tetracycline (Table 3.3.) showed a significant difference between 
the geometric mean for PCR ribotypes 078 (0.93 mg/L) and 002 (0.06 mg/L) 
(P≤0.05) but not between PCR ribotype 027 (0.11 mg/L) and 078 (P=0.06) or 
PCR ribotype 002 and 027 (P=0.62). PCR ribotype 078 strains had the highest 
MIC50 and MIC90 results (both 8 mg/L). The PCR ribotype 002 isolates also had the 
same MIC50 and MIC90 (0.06 mg/L). Whereas, PCR ribotype 027 strains had a 
MIC50 of 0.06 mg/L and the MIC90 was 4 mg/L. All the strains for PCR ribotype 027 
and 002 were susceptible to tetracycline, 45% of PCR ribotype 078 were also 
susceptible, whereas 55% were in the intermediate range of susceptibly (Figure 
3.1. and Appendix 1.5).  
 
3.4.2. Comparison of Geographical Location 
 
The MIC results for the isolates of PCR ribotypes 078 were variable and seemed 
to be specific to locations of isolation for metronidazole and vancomycin, for 
example the Derriford isolates (strains 31 and 32) both had a metronidazole MICs 
of <0.03 mg/L and vancomycin MICs were both 0.5 mg/L (Appendix 1.5). 
Whereas, the Sheffield isolates metronidazole MICs were (strain 59) 0.125 mg/L 
and (strain 60) 0.03 mg/L and vancomycin MICs were both 0.5 mg/L (Appendix 
1.5). The PCR ribotype 078 MIC results for the other antibiotics were similar, for 
example most of the isolates had a MIC of 8 mg/L for ciprofloxacin and 0.06 mg/L 
for erythromycin (Appendix 1.5). The PCR ribotype 027 isolates MICs showed 
there was no variability between the strains for some of the antibiotics, such as 
vancomycin (most strains were 0.5 mg/L), moxifloxacin (all strains 32 mg/L) and 
tetracycline (all strains >128 mg/L), whereas the metronidazole results showed 
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some variability but this was not location specific, for example of the four Bradford 
isolates, two strains (9 and 11) had a MIC of 2 mg/L and the other strain had MIC 
results of 1 mg/L (12) and 4 mg/L (10) (Appendix 1.5). The PCR ribotype 002 MIC 
results were not variable, for example the metronidazole MICs most of the MICs 
were 0.125 mg/L or 0.25 mg/L and the vancomycin results most strains were 0.5 
mg/L (Appendix 1.5). 
 
 
 
 
 
 
   
4
3
 
Table 3.3. Geometric mean minimum inhibitory concentration (MIC) (mg/L), MIC50 (mg/L), range (mg/L) and MIC90 (mg/L) 
of metronidazole (Met.), vancomycin (Van.), ciprofloxacin (Cip.), clindamycin (Clind.), erythromycin (Ery.), linezolid (Lin.), 
moxifloxacin (Mox.) and tetracycline (Tet.) for PCR ribotype (RT) 078, 027 and 002 groups (N=11 strains) using an agar 
incorporation method with Wilkins-Chalgren anaerobe agar and C. difficile cultures grown in Schaedler's anaerobic broth 
(1x104 CFU/plate).   
* defined MIC end-points were difficult to determine due to re-growth at some antimicrobial concentrations for some strains. 
  
   
4
4
 
 
 
 
 
 
 
Figure 3.1. The percentage of strains in each PCR ribotype (RT) group (N=11) (RT078, RT027 and RT002), which 
were in the resistant (R), susceptible (S) or intermediate (I) range when exposed to the antimicrobial agents based 
on CLSI (2007), EUCAST (2014) and BSAC (2013) breakpoints. Abbreviations: metronidazole (Met.), vancomycin 
(Van.), ciprofloxacin (Cip.), clindamycin (Clind.), erythromycin (Ery.), linezolid (Lin.), moxifloxacin (Mox.) and 
tetracycline (Tet.).  
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3.5. Discussion and Conclusion 
 
Antibiotic properties have been known of and exploited since the Roman and 
Egyptian eras, since then new antibiotics and ways to determine bacterial 
resistance have been discovered and developed (Aminov, 2010; Fleming, 1929; 
Wheat, 2001). To investigate which are the most efficacious antibiotics to use as 
treatments for bacterial (or fungal) infections, MIC testing and PCR can be used 
to determine the resistance to antibiotics (Courvalin, 1991; Kahlmeter et al., 
2003). CDI can be caused by the use of some antibiotics, such as fluoroquinolones. 
However, it can also be treated by antibiotics, such as metronidazole or 
vancomycin, depending on the severity of the condition (Al-Nassir et al., 2008; 
Borgmann et al., 2010; Menendez et al., 2001). The present study used AIM to 
characterise and compare the susceptibilities of PCR ribotypes 078, 027 and 002 
to eight antibiotics. The breakpoints used to determine the susceptibility to the 
antibiotics are from BSAC, EUCAST and CLSI, each committee uses different 
antimicrobial susceptibility testing methods to demine the breakpoints: BSAC 
(2013) used disc diffusion method (C. difficile breakpoints were not found for 
ciprofloxacin, erythromycin and linezolid so breakpoints for Staphylococci were 
used), EUCAST (2014) used breakpoints based on ECOFF values, whereas CLSI 
(2007) used the agar dilution method, this method is used in the current study. 
Therefore, the CLSI breakpoints are more relevant, however they might not 
always be able to be used as the CLSI have not tested all antibiotics used in the 
current study. 
 
The geometric mean metronidazole MIC results suggested that there was a 
substantial difference between the susceptibilities of the PCR ribotype 078 and 
027 groups to certain antimicrobial agents. PCR ribotype 078 was more 
susceptible to metronidazole (0.08 mg/L) than PCR ribotype 027 (1.37 mg/L) but 
just as susceptible as PCR ribotype 002 (0.18 mg/L) (Table 3.3.). However, this 
is not consistent with Moura et al. (2013) whose results, using AIM, for PCR 
ribotype 027 (0.125 mg/L to 0.5 mg/L) and PCR ribotype 078 (0.125 mg/L) were 
very similar. The marked difference in the PCR ribotype 078 range of MICs 
suggests variations of individual strains  (or the culture media used), within the 
same PCR ribotype, showing varying levels of susceptibly to metronidazole (Table 
3.3. and Appendix 1.5). There was a marked difference between the geometric 
mean metronidazole MICs of the PCR ribotype 078 and 002 groups which suggests 
there was a noticeable variation between the two PCR ribotypes despite their 
MIC50, MIC90 and ranges being so close (Table 3.3.). These results were less than 
the breakpoint for metronidazole (≤8 mg/L) set by CLSI (2007), so it can be 
concluded that all of the strains studied within the PCR ribotype groups studied 
were susceptible to metronidazole (Appendix 1.5). Bolton and Culshaw (1986) 
observed metronidazole concentrations within the faecal contents of CDI patients 
are approximately 9.3 mg/L, however, Freeman et al. (2007) observed 7-25% 
less than this level in an in vitro model of the human colon, which was still higher 
than the MICs of metronidazole for all PCR ribotypes in the present study.     
 
The MIC results for vancomycin suggested there were no differences in 
susceptibility between the PCR ribotype groups. These results are supported by 
Debast et al. (2013) whose results showed no noticeable difference in 
susceptibility between PCR ribotype 078 (MIC50 0.5 mg/L and MIC90 1 mg/L) and 
027 (MIC50 0.5 mg/L and MIC90 0.5 mg/L) (Table 3.3). Similarly, the results from 
the present study for PCR ribotype 078 (MIC50 0.5 mg/L and MIC90 1 mg/L) and 
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027 (MIC50 0.5 mg/L and MIC90 0.5 mg/L) were within the accepted error for MIC 
testing methods (one doubling dilution) (Table 3.3). As these MIC results are 
below the breakpoint set by EUCAST (2014) for vancomycin (≤2 mg/L) it can be 
concluded that all of the strains studied within the PCR ribotype groups in this 
study were susceptible to vancomycin (Appendix 1.5). Baines et al. (2009) found 
with gut model studies that vancomycin levels within the gut could get to >550 
mg/L which is more than enough to be active against the C. difficile PCR ribotypes 
in the present study. 
 
Linezolid geometric mean MIC results were not noticeably different compared to 
vancomycin and metronidazole. The linezolid MICs against PCR ribotype 027, in 
the present study, showed that PCR ribotype 027 had a geometric mean MIC of 
0.25 mg/L for linezolid compared to 1.37 mg/L for metronidazole and 0.53 mg/L 
for vancomycin. Similarly, Baines et al. (2011) also showed PCR ribotype 027 
demonstrated a higher metronidazole geometric mean MICs (1.31 mg/L) 
compared to linezolid (1.15 mg/L) and vancomycin (0.88 mg/L) which is 
consistent with the current study (Table 3.3.). The linezolid resistance breakpoint 
for Staphylococci species is >4 mg/L, this suggests PCR ribotype 078 (0.73 mg/L), 
PCR ribotype 027 (0.25 mg/L) and PCR ribotype 002 (0.5 mg/L) were susceptible 
to linezolid (BSAC, 2013). Lode et al. (2001) found the average linezolid faecal 
concentration from 12 volunteers to be 7.1 mg/kg at four days and 3.0 mg/kg at 
eight days (dosage of linezolid: two 600 mg tablets a day over seven days) 
therefore this suggests all three PCR ribotype would be susceptible to gut 
concentrations of linezolid (if mg/kg are assumed equivalent to mg/L). 
 
In this study erythromycin geometric mean MICs were the highest compared to 
the other antibiotics. This correlates with the study performed by Mutlu et al. 
(2007) which showed erythromycin MIC50 (≥32 mg/L) and MIC90 (≥32 mg/L) were 
highest compared to a range of antibiotics including metronidazole (MIC50 1 mg/L 
and MIC90 2 mg/L), vancomycin (MIC50 2 mg/L and MIC90 4 mg/L), clindamycin 
(MIC50 8 mg/L and MIC90 16 mg/L) and tetracycline (MIC50 ≥1 mg/L MIC90 2 mg/L) 
(Table 3.3.). The resistance breakpoints for other Gram-positive bacteria, such as 
staphylococci, are >2 mg/L for erythromycin (BSAC, 2013). Therefore, the C. 
difficile PCR ribotype 027 strains in this study were resistant to erythromycin (MICs 
were all 128 mg/L), whereas C. difficile PCR ribotype 078 (0.50 mg/L) and 002 
(0.25 mg/L) were susceptible to erythromycin (Table 3.3.). C. difficile was more 
susceptible to clindamycin than metronidazole and vancomycin in the present 
study but not in the study of Mutlu et al. (2007). The susceptibility breakpoint for 
C. difficile for clindamycin is ≤2 mg/L, the PCR ribotype 027 (0.44 mg/L), 078 
(0.09 mg/L) groups were susceptible to clindamycin, whereas the PCR ribotype 
002 (3.31 mg/L) group is in the intermediate category for clindamycin 
(intermediate: 4 mg/L, resistance: ≥8 mg/L) (Table 3.3.) (CLSI, 2007). Chilton et 
al. (2014) found the concentrations of clindamycin had a peak range of 35.1 to 
62.3 mg/L in a simulated model of the colon, suggesting that all ribotypes would 
be affected by the gut concentrations within the gut. It was also found by Solomon 
et al. (2011) that most PCR ribotype 078 isolates studied did not possess ermB, 
whereas, most of the PCR ribotype 027 isolates studied did have the ermB gene, 
which could be the reason for the difference in the present studies erythromycin 
results. However, Spigaglia and Mastrantonio (2004) found isolates which were 
erythromycin resistant but clindamycin susceptible (which is also shown in the 
PCR ribotype 027 group in present study) did not possess the ermB gene. The 
difference in  the PCR ribotype 027 and 078 clindamycin results may be due the 
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mefA gene, which have been found in other Clostridium species, like C. perfringens 
and has been linked to transposons associated with C. difficile (Soge et al., 2009). 
If C. difficile strains acquired the mefA gene the bacterium would be more resistant 
to erythromycin but not to clindamycin (Leclercq, 2002). In the study of Mutlu et 
al. (2007) C. difficile was shown to be more susceptible to tetracycline than 
metronidazole and vancomycin, which is consistent with the results of the current 
study. CLSI (2007) breakpoints for tetracycline are ≤4 mg/L, therefore, all of the 
strains within all the PCR ribotype groups in the current study were susceptible to 
tetracycline (PCR ribotypes 078: 0.93 mg/L, PCR ribotype 027: 0.11 mg/L, PCR 
ribotype 002: 0.06 mg/L) (CLSI, 2007)(Table 3.3). In contrast, Bakker et al. 
(2010) found that the PCR ribotype 078 strains which were resistant to tetracycline 
contained the tetM gene, whereas, Stabler et al. (2009) found that PCR ribotype 
027 has no tetracycline resistance genes (Bakker et al., 2010; Dong et al., 2014; 
Stabler et al., 2009).  Rashid et al. (2013) found the faecal concentrations of 
doxycycline in 16 volunteers, which is a member of the tetracycline antimicrobial 
family. The study found an average of 0.98 mg/kg of doxycycline at 16 weeks of 
taking 40 mg capsules. If this is the case for tetracycline then the concentration 
is higher than all three PCR ribotypes’ geometric mean MICs observed in the 
present study, so it could have an antimicrobial effect in vivo. Conversely, the 
MIC50 suggests that this concentration of tetracycline would not be effective 
against at least half of the strains, in this study. However, this may not be relevant 
in vivo in CDI as tetracycline has been found, by Brown et al. (2013), to have a 
low risk of causing CDI so may have little or no effect on the rest of the gut 
microflora.  
 
Compared to ciprofloxacin and moxifloxacin C. difficile was more susceptible to 
vancomycin and metronidazole in the present study, which reflects the report of 
Bourgault et al. (2006). In this study the authors reported that ciprofloxacin (MIC50 
>128 mg/L, MIC90 >128 mg/L) and moxifloxacin (MIC50 64 mg/L, MIC90 64 mg/L) 
MIC50 and MIC90 results were higher than the results for metronidazole (MIC50 0.25 
mg/L MIC90 0.05 mg/L) and vancomycin (MIC50 1 mg/L; MIC90 1 mg/L). The study 
also had a higher range for both ciprofloxacin (16 mg/L to >128 mg/L) and 
moxifloxacin (2 mg/L to >128 mg/L) than metronidazole (≥0.06 mg/L- 1 mg/L) 
and overlapped with vancomycin MICs (≥0.05 mg/L to 4 mg/L), which is similar 
to the results in the present study. Bourgault et al. (2006) also found that for 
moxifloxacin, PCR ribotype 027 had higher MIC50 (64 mg/L) and MIC90 (128 mg/L) 
results compared to the other PCR ribotypes that were tested and this is consistent 
with the results in the present study (MIC50 32 mg/L MIC90 32 mg/L) (Table 3.3.). 
The MIC results for ciprofloxacin and moxifloxacin showed that overall C. difficile 
is more resistant to ciprofloxacin than moxifloxacin which reflects prior studies, 
however the study of Wilcox et al. (2000) did not specify all of the PCR ribotypes 
that were used. The resistance breakpoint for moxifloxacin (≥8 mg/L) set by CLSI 
(2007) suggests the PCR ribotype 027 group (geometric mean MIC: 32 mg/L) was 
resistant to moxifloxacin, whereas, the PCR ribotype 078 group and the PCR 
ribotype 002 group were susceptible (susceptible category is ≤2 mg/L) (Table 
3.3.). Rodriguez et al. (2014) also demonstrated resistance to moxifloxacin in PCR 
ribotype 078 (using E-testing) and resistance was associated with a mutation 
within the gryA gene which encodes for part of DNA gyrase. Additionally, Saxton 
et al. (2009) found PCR ribotype 027 isolates with resistance to moxifloxacin 
(using agar incorporation method) also had a mutation in the gryA gene and a 
mutation in the gryB gene. The resistance breakpoint for Staphylococci to 
ciprofloxacin is >1 mg/L, and if this breakpoint is used for C. difficile, the results 
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of the current study showed that all the PCR ribotypes were resistant to 
ciprofloxacin (PCR ribotype 027: 68.16 mg/L; PCR ribotype 078: 7.51 mg/L; PCR 
ribotype 002: 10.29 mg/L) (Table 3.3.) (BSAC, 2013). Saxton et al. (2009) found 
that the mean moxifloxacin concentrations in a simulated model of the colon were 
43 mg/L, this suggests that the moxifloxacin levels would be affective against PCR 
ribotype 002 and 078 but not PCR ribotype 027. Whereas, the gut mean 
concentrations for ciprofloxacin were 139 mg/L which is much higher than the 
geometric mean MICs of all PCR ribotypes in the current study (Saxton et al., 
2009). 
 
The geographical location of the isolates may have an influence of the 
metronidazole and vancomycin MIC results for PCR ribotype 078 strains, as there 
was some variation between the results for different locations of isolation, such as 
between Derriford and Sheffield isolates (Appendix 1.5). However with PCR 
ribotype 027 and 002 and other antimicrobials the MIC results may not be affected 
by the location of isolation as there was little variation between geographical 
locations (Appendix 1.5). 
 
In conclusion, C. difficile PCR ribotype 078 was more susceptible to most of the 
antibiotics tested than PCR ribotype 027 and 002, including metronidazole and 
vancomycin, which are common treatments for CDI. PCR ribotype 078 was the 
only PCR ribotype to be susceptible to all the antibiotics used in this study (Al-
Nassir et al., 2008; BSAC, 2013; EUCAST, 2014; Menendez et al., 2001). The 
results from this study suggest that all the strains from all three PCR ribotypes 
were susceptible to only three antibiotics: vancomycin, metronidazole and 
linezolid (Figure 3.1. and Appendix 1.5). The clindamycin showed all the strains in 
the PCR ribotype 027 and 078 group were susceptible however most of the PCR 
ribotype 002 strains (64%) were resistant (Figure 3.1. and Appendix 1.5). The 
results also showed that only 45% of the PCR ribotype 078 were susceptible to 
tetracycline compared to 100% of the PCR ribotype 027 and 002 strains (Figure 
3.1. and Appendix 1.5). As breakpoints are good indicators of whether an 
antibiotic would be a good treatment it would be a fair conclusion that linezolid 
(according to these results) would be a good alternative treatment for CDI caused 
by PCR ribotype 078, 027 and 002 (Angeby et al., 2012; Jorgensen and Ferraro, 
2009). 
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4. Comparing the Biofilm Production and 
Resistance to Antibiotics of Three PCR 
Ribotypes of Clostridium difficile 
 
4.1. Introduction 
 
Bacteria can grow in two forms, planktonic (individually) or within a self-produced 
polymeric matrix, called a biofilm (Ðapa et al., 2013). Bacterial cells are believed 
to attach to a surface and subsequently replicate into micro-colonies which mature 
by producing an extracellular polymeric substance (EPS) matrix. The bacteria also 
continue to multiply and produce separate colonies within the biofilm (Conibear et 
al., 2009; Davey and O'Toole, 2000; Semenyuk et al., 2014). The EPS matrix may 
comprise of extracellular DNA (eDNA), proteins and polysaccharides (Hall-
Stoodley and Stoodley, 2009; Semenyuk et al., 2014). Biofilms are the most 
common form of microbial growth and can contain more than one species of 
bacteria, they can also contain species of algae, protozoa and fungi (Burmolle et 
al., 2014). Biofilms are believed to protect the bacteria to environmental changes, 
such as oxygen stress, dehydration, and they may increase the resistance to 
antibiotics by up to a 1000-fold more compared to planktonic cells (Burmolle et 
al., 2014; Charlebois et al., 2014; Ðapa et al., 2013; Mah and O'Toole, 2001). 
Additionally, biofilms can grow on organic surfaces, such as teeth in the form of 
dental plaque, and within the lungs of patients with cystic fibrosis (CF). Growth 
can also occur on inorganic surfaces, for example catheters and stents (Hoiby et 
al., 2011). As a result of this property it is thought that biofilms are associated 
with 65-80% of nosocomial infections and the resulting healthcare costs have 
been estimated at >$1 billion annually (Mah and O'Toole, 2001; Sawhney and 
Berry, 2009). 
 
Within the human body, macrophages are a first line of defence against bacterial 
infections. Macrophages use phagocytosis to eliminate pathogenic microbes, for 
example bacteria, and this involves binding to the bacteria using the CD64 
receptors on the macrophage membrane (Hernández-Jiménez et al., 2013). Once 
bound by the macrophage, a bacterium is engulfed into the cell in a phagosome, 
in which the pathogen is destroyed via endosomal and lysosomal fusion, which 
involves the release of toxins and enzymes which breakdown the pathogenic 
components (Flannagan et al., 2012; Hernández-Jiménez et al., 2013). Biofilms 
protect the bacteria from this process, this may be shown by the differential 
expression of CD64 receptors (Hernández-Jiménez et al., 2013; Jefferson, 2004). 
Hernández-Jiménez et al. (2013) observed that macrophages preferentially 
attacked E. coli planktonic cells over those within a biofilm, this was shown by an 
increase in expression of CD64 receptors, on the macrophage cell membrane, in 
the presence of the planktonic cells, whereas, there was no elevation in the 
presence of bacteria in a biofilm (Hernández-Jiménez et al., 2013).  
 
Biofilms have been shown to reduce the susceptibility of bacteria to antibiotics. 
There are several hypotheses as to why this is the case, one is thought to be due 
to the inability of the antibiotic to penetrate the biofilm or that antibiotics may 
demonstrate a slow diffusion rate through the biofilm (Jefferson et al., 2005). 
Jefferson et al. (2005) found vancomycin took approximately 60 minutes to bind 
to bacteria in the deeper layers of a S. aureus biofilm compared to taking 
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approximately five minutes to bind to planktonic cells of the same organism. 
Consequently, some antibiotics could become inactivated more rapidly than they 
could penetrate through the biofilm, due to microbial resistance gene products, 
binding to charged polymers within the biofilm, or interactions with antibiotic-
degrading enzymes and/or dead cells (Anderl et al., 2000; Hall-Stoodley and 
Stoodley, 2009; Stewart and Costerton, 2001). Another hypothesis is due to 
differences in physiological properties of the bacterial cells, for example the growth 
rate of the cells or age of the biofilm (Anderl et al., 2000). Duguid et al. (1992) 
found S. epidermidis biofilms increased in susceptibly to ciprofloxacin as the µmax 
within the biofilm increased, owing to more targets (DNA gyrase and 
Topoisomerase IV) for the ciprofloxacin to modify (Drlica and Zhao, 1997). 
Additionally, Anwar and Costerton (1990) concluded the older a Pseudomonas 
aeruginosa biofilm the more resistant to antibiotics (tobramycin and piperacillin) 
the bacteria became, this may be due to the biofilm becoming thicker or the 
growth rate of the bacteria within the biofilm slowing down (Anwar et al., 1992; 
Monzón et al., 2001). Another factor that may help to explain reduced 
antimicrobial activity against microbial biofilms is the atmospheric characteristics 
of the biofilm as the oxygen gradients can differ throughout the layers of a biofilm, 
so much so that it creates anaerobic areas in deeper layers. These areas produce 
acidic waste and decrease the pH, which may inhibit the action of the antibiotics 
(Stewart and Costerton, 2001). Varying nutrient levels, within a biofilm, may also 
contribute to slow bacterial growth or complete cessation of growth, this therefore 
also increases the resistance to antibiotics (Mah and O'Toole, 2001). Multispecies 
biofilms have been found to have greater resistance to antibiotics than single 
species biofilms (Burmolle et al., 2014; Lopes et al., 2012). For example, Lopes 
et al. (2012) found bacteria which are isolated from CF patients, such as 
Dolosigranulum pigrum and Inquilinus limosus, demonstrated higher MBEC, to 
certain antibiotics, when cultured within a biofilm containing P. aeruginosa, a 
common pathogen in patients with CF, than in their respective individual single 
species biofilms.  
 
C. difficile has been found to penetrate the mucus layer within the gut so it can 
adhere to colonic epithelial cells and produce a biofilm on the gut wall within 
mammals, such as mice (Crowther et al., 2014; Reynolds et al., 2011; Twine et 
al., 2009). Additionally, Crowther et al. (2014) used an in vitro gut model to find 
that a biofilm (containing C. difficile and other gut bacteria) was the more 
dominant structure over planktonic cells. Some C. difficile ribotypes have flagella 
at the surface of the cell, which may aid in the adherence to the gut wall, the 
bacterium divides and then starts the production of the EPS matrix (Stephens, 
2002; Tasteyre et al., 2001; Twine et al., 2009). Tasteyre et al. (2001) found that 
flagellated strains for C. difficile bound to mouse cecum more than non-flagellated 
strains. The flagella are made of proteins including the flagellar cap (FliD) and 
flagellin (FliC) proteins, which both aid in the adherence of the C. difficile to the 
mucus layer on the gut cell wall, FliD also aids in the attachment of the cells 
(Baban et al., 2013; Barketi-Klai et al., 2014; Tasteyre et al., 2001). The agr 
quorum sensing locus has been found by Martin et al. (2013) to increase the 
production of flagella in PCR ribotype 027 strains. Pili are another important 
component factor in the ability of certain bacterial species to produce biofilms, for 
example H. influenzae. The genes which encode for the pili, the Type IV pilin 
biogenesis components, in other biofilm-producing clostridia, for example C. 
perfringens, have also been found in C. difficile (Murphy and Kirkham, 2002; 
Piepenbrink et al., 2014; Varga et al., 2008). As well as pili, C. difficile has also 
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been found to produce the second messenger 3’,5’-cyclic diguanylic acid (c-di-
GMP) and Purcell et al. (2012) found that when c-di-GMP is in high levels the 
bacteria are clumped together and produce long thin fibres similar to pili. C. 
difficile also possesses a crystalline surface layer (S-layer) which aids in the 
adherence to the gut wall (Cerquetti et al., 2000; Ðapa et al., 2013; Ðapa and 
Unnikrishnan, 2013). One protein needed to for the maturation of the S-layer is 
cell wall protein (Cwp) 84 (Ðapa et al., 2013; Ðapa and Unnikrishnan, 2013; 
Hammond et al., 2014). Ðapa et al. (2013) found the C. difficile with a mutation 
in the cwp84 gene did not form a biofilm as well as the wild-type C. difficile.  
 
As well as the aforementioned properties needed for biofilm production, there is 
an essential process, known as quorum sensing, which is also needed for C. 
difficile to form a biofilm (Ðapa et al., 2013; Ðapa and Unnikrishnan, 2013). 
Quorum sensing is a cell to cell signalling process, usually using chemicals, which 
is required for almost all bacteria to communicate (not just for biofilm 
production)(Miller and Bassler, 2001). In C. difficile the LuxS protein plays a role 
in this process. Ðapa et al. (2013) found that C. difficile strains with a mutation in 
the luxS gene could not form a monolayer, let alone a biofilm. (Ðapa et al., 2013; 
Ðapa and Unnikrishnan, 2013; Hammond et al., 2014).  
 
Spores and toxins are also produced in a C. difficile biofilm structure (Figure 4.1.) 
(Crowther et al., 2014; Semenyuk et al., 2014). Semenyuk et al. (2014) showed 
that C. difficile biofilms form after 24 hours and cell debris starts to be detected. 
After three days of growth the biofilm contains vegetative cells, spores and dead 
cells, whereas after six days there were more spores than viable cells. It was 
discovered that cell growth continued within the biofilm at 24 hours, additionally, 
toxin was also produced at 24 hours, in the three day biofilms toxin was detected 
in all samples in the study. There was a significant increase in toxin levels in the 
six day biofilms. When the biofilm is mature (in P. aeruginosa biofilms) bacterial 
cell are dispersed to start the cycle again. The spores produced in a C. difficile 
biofilm may also be part of this process of biofilm dispersal and are a potential 
factor in the recurrence of CDI (Crowther et al., 2014; Stoodley et al., 2002). 
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Figure 4.1. Proposed C. difficile (    ) biofilm production over six days. C. difficile attaches to the surface, multiplies and 
starts to produce extracellular polymeric substances (  ) before 24 hours. Spores (  ), toxin (  ) and cell debris (    ) are 
detected after three days. After six days there are more spores, toxin and cell debris than viable cells and new colonies are 
formed. (Based on Semenyuk et al. (2014)). 
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4.2. Aims and Objectives 
 
The aims of this study are to compare the biofilm production of three C. difficile 
PCR ribotype groups (PCR ribotype 078, 027 and 002). Furthermore, the 
susceptibility of the C. difficile biofilms to metronidazole and vancomycin will also 
be assessed. 
 
 This will be achieved by producing batch cultures of 10 C. difficile strains of 
each PCR ribotype group then aliquoting the cultures into 96-well microtitre 
plates and allowing the biofilm to grow over three and six days. The biofilms 
will be stained with crystal violet and the absorbance determined.  
 
 The susceptibility of biofilms to antimicrobial agents will be assessed by 
growing biofilms of each strain using the Calgary Biofilm Device (CBD) and 
placing the biofilm into culture media with different concentrations of 
metronidazole or vancomycin. 
 
4.3. Materials and Methods 
 
4.3.1. C. difficile strains 
 
The strains in each of the experiments were prepared using methods in Section 
1.2.1. 
 
The biofilm growth (Section 4.3.2.), biofilm minimum inhibitory concentration 
(bMIC), and Minimum Biofilm Eradication Concentrations (MBEC) (Section 4.3.4.) 
experiments all used 10 C. difficile strains each from PCR ribotype 078, 027 and 
002 groups in triplicate.  
 
In the 96-well microtitre plate biofilm assay experiment (Section 4.3.3) 11 C. 
difficile strains each from PCR ribotypes 078, 027 and 002 were used in triplicate.  
 
In the assessment of biofilm total viable counts and spore counts using Calgary 
Biofilm Device (CBD) Assay (Section 4.3.5.) three strains from each C. difficile 
PCR ribotype were evaluated (PCR ribotype 078, 027 and 002) in triplicate.  
 
All experiments used the control strains, E4 (PCR ribotype 010) and ATCC 700057 
(VPI 11186) (PCR ribotype 038) in triplicate. 
 
4.3.2. Preparation of Biofilm Growth Assay 
 
The methods in this study adapt the methods of Dawson et al. (2012). The present 
study used 96-well microtitre plates (FB56412, Fisher Scientific) whereas Dawson 
et al. (2012) used 24-well microtitre plates (Nunc). 
 
A 1:10 dilution of an overnight culture of each C. difficile isolate was aseptically 
aliquoted into BHIS broth in two 96-well microtitre plates (FB56412, Fisher 
Scientific) as displayed in Figure 4.2. The 96-well microtitre plates were wrapped 
in Parafilm® M (PM-992) to reduce evaporation of liquid and incubated at 37°C 
for three and six days respectively in an anaerobic cabinet. BHIS was removed 
from each well and disposed of the wells were then washed three times with sterile 
PBS. Subsequently, 200 µl of 1% (w/v) crystal violet (Sigma-C6158-100g) diluted 
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in 95% industrial methylated spirit (IMS) (Fisher-M14450/17) was aliquoted into 
each well and left at room temperature for 30 minutes to stain the contents of the 
well. The wells were then washed gently five times with PBS and then 200 µl of 
methanol (Fisher- M/4000 PC17) was aliquoted into each well and left for 15 
minutes at room temperature. The absorbance of the 96-well microtitre plate wells 
was read at 590 nm (using a microtitre plate spectrometer (Original multiskan EX-
Thermo Scientific - 51118170)) using the stained control BHIS well as the blank. 
This process was repeated on the sixth day of growth. Biofilm biomass (via OD590) 
was measured in triplicate and the average was calculated. 
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Figure 4.2. The arrangement of C. difficile strains in the 96-well microtitre 
plate. So each strain in triplicate. 
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4.3.3. Preparation of Biofilm Total Viable and Spore Counts using a 96-
Well Microtitre Plate Biofilm Assay 
 
A 1:10 dilution in BHIS of an overnight culture (prepared from Section 1.2.) of 
each C. difficile isolate was aseptically aliquoted into two 96-well microtitre plates 
(FB56412, Fisher Scientific). The 96-well microtitre plates were wrapped in 
Parafilm® M (PM-992) to reduce evaporation of liquid and then incubated at 37°C 
for three and six days in independent experiments, in an anaerobic cabinet. An 
additional microtitre plate was prepared to assess biofilm at the zero hour time 
point. BHIS was carefully removed from each well and disposed of, the wells were 
then washed twice with sterile pre-reduced PBS. The biofilm was disrupted by 
adding 100 µl PBS into the wells and agitating at 1300 rpm for 10 minutes using 
an orbital shaker (Obris personal plate Shaker, Mikura, W, Sussex, Serial number: 
1959). A 10-fold dilution series was produced of the suspension in pre-reduced 
PBS (Neat to 10-5). Each dilution (20 µl) was spread onto Brazier’s agar. The 96-
well microtitre plate was placed into a hot cabinet at 65°C for 20 minutes to kill 
of vegetative cells in order that spore counts could be determined. An initial 
comparison of the effectiveness of heat-inactivation of vegetative C. difficile 
compared to alcohol-shocking C. difficile cultures showed that both methods were 
effective and that spore counts were almost identical (data not shown), therefore 
heat inactivation methods were used in this study. Each spore dilution (20 µl) was 
spread on Brazier’s agar (with supplements). The plates were incubated for 48 
hours in an anaerobic cabinet at 37°C. The dilution with between 20 to 200 CFUs 
(where possible) was counted. Once counted, CFU/ml was calculated using the 
equation below, in triplicate, and viable counts were expressed as log10 CFU/ml: 
 
𝐶𝐹𝑈 𝑝𝑒𝑟 𝑚𝑙 = (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐹𝑈𝑠 × 1/𝑛) × 50 
(n = the dilution as a decimal in which CFUs were counted) 
 
4.3.4. Biofilm Minimum Inhibitory Concentration and Minimum Biofilm 
Eradication Concentrations 
 
This study modified methods of Ooi et al. (2010) who studied S. aureus biofilms 
and a range of antibiotics and the cultures were grown with Mueller-Hinton broth 
and agar. Conversely, in the present study C. difficile was cultured in BHIS and on 
Braziers agar and metronidazole (M3761-25G, Sigma-Aldrich, Gillingham) and 
vancomycin hydrochloride (V2002-1G, Sigma-Aldrich, Gillingham) were the 
antimicrobials evaluated.  
 
An overnight culture of each C. difficile strain was aliquoted 1:10 into fresh BHIS 
in 96-well microtitre plate (167008, Thermo Scientific) in the same arrangement 
as in Figure 4.2. A CBD lid (445497, Thermo Scientific) was placed onto the 96-
well microtitre plate in place of the lid. The microtitre plate was then wrapped in 
Parafilm® M and incubated in the anaerobic cabinet at 37°C for four days 
(statically) to allow biofilms to form. An experimental duration of four days was 
selected, since prior research by Semenyuk et al. (2014) indicated that after six 
days C. difficile biofilms were dominated by spores. The metronidazole (M3761-
25G, Sigma-Aldrich, Gillingham) and vancomycin hydrochloride (V2002-1G, 
Sigma-Aldrich, Gillingham) 1024 mg/L solutions (30.72 mg of antibiotic powder in 
30 ml of sterile distilled water) were prepared in BHIS as described in Figure 4.3. 
Each concentration (512 mg/L to 0.5 mg/L) was aliquoted into microtitre plates 
(one each concentration), 200 µl per well, and left in an anaerobic cabinet to pre-
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reduce overnight. On the fourth day of growth each CBD was transferred to a 
microtitre plate with antibiotics, and incubated in an anaerobic cabinet at 37°C 
overnight. OD590 was determined from the initial 96-well microtitre plate using the 
blank of BHIS. Subsequently, the CBDs were transferred to sterile microtitre plates 
containing 200 µl of fresh pre-reduced BHIS and incubated in an anaerobic cabinet 
at 37°C overnight, the absorbance was then read at 590 nm. 
 
The bMIC and MBEC were determined by interpreting the absorbance readings of 
the BHIS with antibiotics (bMIC) and the BHIS after antibiotic treatment (MBEC) 
for each triplicate of each strain. The blank BHIS reading was taken subtracted 
from each of the biofilm readings and the average of the triplicates was 
determined. The bMIC was defined as: the lowest concentration of antimicrobial 
that prevents planktonic growth in wells containing antimicrobials and biofilms. 
The MBEC was defined as: the lowest antimicrobial concentration that prevents 
planktonic growth when biofilms, attached to CBD lids, were transferred into fresh 
BHIS broth with no antimicrobials. As the blank BHIS absorbance readings varied 
due to staining of residual medium, C. difficile growth was classified an OD590 of 
more than 0.08. Geometric mean bMIC and MBEC values were calculated (results 
<0.5 mg/L were classed as 0.5 mg/L to work out the geometric mean) and the 
MIC ranges were also found. 
 
4.3.5. Preparation of Biofilm Total Viable and Spore Counts using Calgary 
Biofilm Device (CBD) Assay 
 
An overnight culture of each C. difficile strain was aliquoted 1:10 into fresh pre-
reduced BHIS into five 96-well microtitre plates (167008, Thermo Scientific). A 
CBD (445497, Thermo Scientific) was placed onto the 96-well microtitre plates in 
place of the lid. The microtitre plates were then wrapped in Parafilm® M and 
incubated in the anaerobic cabinet at 37°C for two and four days, one was placed 
on a microplate shaker at 1300 rpm for four days, one microtitre plate was tested 
the same day to obtain the day zero result. After the growth period, the pegs on 
the CBD were snapped off using sterile pliers, and placed individually into 1 ml of 
pre-reduced PBS, then vortexed at 25 Hz for 10 seconds. C. difficile total viable 
counts and spore counts were determined as described above in Section 4.3.3.   
 
4.3.6. Statistical Analysis  
 
The biofilm growth results (Section 4.4.1.) were assessed for normality of 
distribution and homogeneity of variance using SPSS and analysed using the 
ANOVA statistical test. A P-value of ≤0.05 was considered statistically significant.  
 
The bMIC and MBEC results (Section 4.2.4) and the viable and spore count data 
in 96-well microtitre plates (Section 4.4.2.) and on BCD (Section 4.4.4.) were 
assessed for normality of distribution and homogeneity of variance using SPSS 
and analysed using the Kruskal-Wallis statistical test. A P-value of ≤0.05 was 
considered statistically significant. 
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Figure 4.3. The preparation of 1024 mg/L antibiotic solutions was diluted in 
supplemented Brain Heart Infusion broth with supplements (BHIS).   
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4.4. Results  
 
4.4.1. Biofilm Growth 
 
Production of biofilm biomass was measured at three and six days using a crystal 
violet staining assay. All PCR ribotype 078 strains demonstrated a wide range of 
average absorbance readings (OD590 0.06 to 0.22) at three days of growth, 
whereas the PCR ribotype 027 group (OD590 0.09 to 0.16) and 002 (OD590 0.06 to 
0.08) readings were similar. After six days of growth the PCR ribotype 078 had 
the widest range (OD590 0.16 to 0.56), PCR ribotype 027 (OD590 0.04 to 0.14) and 
002 (OD590 0.03 to 0.12) readings were similar (Appendix 1.5.). The PCR ribotype 
078 group had the highest average biofilm biomass at three days (OD590 0.12), 
however it was not significantly higher than PCR ribotype 027 average group 
(OD590 0.11) (P=0.54), whereas it was significantly higher than PCR ribotype 002 
(OD590 0.07) (P≤0.05). At six days of growth PCR ribotype 078 (OD590 0.28) had 
a significantly higher biofilm growth than PCR ribotype 027 (OD590 0.08) (P≤0.001) 
and PCR ribotype 002 (OD590 0.08) (P≤0.001) PCR ribotype 078 strains had a 
significant increase between three days and six days (P≤0.001), the biggest 
increase in biofilm biomass. The PCR ribotype 002 strains had the lowest biofilm 
biomass out of the three PCR ribotypes, however there were not significantly 
different to the results for PCR ribotype 027 (day three: P=0.80, day six: P=0.84). 
The increase for PCR ribotype 002 between three and six days was not significant 
(P=0.58). The results for the PCR ribotype 027 group shows an insignificant 
decrease in biofilm biomass between three and six days (P=0.30) (Figure 4.4.). 
Interestingly, it was observed that C. difficile PCR ribotype 078 cultures 
aggregated substantially in 5 ml volumes of BHIS broth in prior experiments, 
whereas PCR ribotypes 027 had little aggregate and 002 cultures did not 
aggregate (Figure 2.4).    
 
4.4.2. Biofilm Total Viable Count and Spore Count in a 96-Well Microtitre 
Plate Biofilm Assay. 
 
The average total viable count within a biofilm for all the PCR ribotypes had a 
significant increase between zero and three days of growth (Figure 4.5). PCR 
ribotype 078 total viable counts were 2.71 log10 CFU/ml at day zero and increased 
to 5.47 log10 CFU/ml at day three (P≤0.001) then at day six the total viable count 
was 5.17 log10 CFU/ml (P≤0.001), resulting in a 1.91 log10-fold increase overall. 
The spore counts for PCR ribotype 078 increased from 1.72 log10 CFU/ml at day 
zero to 3.96 log10 CFU/ml on day three (P≤0.001) and then to 4.58 log10 CFU/ml 
after six days of growth (P≤0.001), so there was a 2.65 log10-fold increase overall. 
The viable count was significantly higher than the spore count at every time point 
(day zero: 1.57 log10-fold; day three: 1.16 log10-fold; day six: 1.13 log10-fold) 
(P≤0.001) (Appendix 1.4).  
 
PCR ribotype 027 total viable counts increased from 2.76 log10 CFU/ml to 4.94 
log10 CFU/ml (P≤0.001) over three days then increased to 5.87 log10 CFU/ml 
(P≤0.001) at day six (Figure 4.5). Overall, there was a 2.13 log10-fold increase. 
There was an increase from 0.85 log10 CFU/ml to 4.27 log10 CFU/ml over three 
days (P≤0.001) for spore count and then a further increase to 5.32 log10 CFU/ml 
after six days of biofilm growth (P≤0.001). At all the time points the viable count 
was significantly higher than the spore count (P≤0.001) (Appendix 1.4). 
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Figure 4.4. Mean biofilm biomass (optical density (OD
590
) (±SE)) measured at day three and six of biofilm growth, for 
C. difficile PCR ribotypes (RT) 078, 027 and 002 (N=11 strains of each PCR ribotype). Biofilms were grown in BHIS 
broth and stained with crystal violet to determine the biomass. 
 
* statistically significant difference P-value ≤0.05 
*** statistically significant difference P-value ≤0.001 
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Figure. 4.5. Average total viable count (VC) and spore count (SC) (log
10
 colony forming units (CFU)/ml (±SE)) in 
biofilms formed in a 96-well microtitre plate after zero, three and six days growth, for PCR ribotype (RT) 078, 027 and 
002 (N=11 strains of each PCR ribotype) in BHIS broth. 
* statistically significant difference P-value ≤0.05 
** statistically significant difference P-value ≤0.01 
*** statistically significant difference P-value ≤0.001 
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The PCR ribotype 002 biofilm total viable counts increased from 3.28 log10 CFU/ml 
at day zero to 5.71 log10 CFU/ml at day three (P≤0.001), then remained constant 
until day six (P=0.95). Overall, there was a 2.42 log10-fold increase between day 
zero and day six. PCR ribotype 002 spore counts were 1.20 log10 CFU/ml at day 
zero and increased to 2.34 log10 CFU/ml (P≤0.001) and 5.27 log10 CFU/ml after 
three and six days respectively (P≤0.001) (Figure 4.5.). After six days of growth 
the spore count increased 4.07 log10-fold. The spore count was significantly lower 
at every time point than the total viable count (P≤0.001) (Appendix 1.4). 
 
There was significantly higher total viable cell counts from biofilms in the PCR 
ribotype 002 biofilm at day zero (Figure 4.5.) than PCR ribotype 078 (1.21 log10-
fold) (P≤0.001) and 027 (1.19 log10-fold) (P≤0.001) however there were similar 
total viable counts between PCR ribotypes 078 and 027 (P=0.91). The spore 
counts from biofilms at day zero for PCR ribotype 078 were significantly higher 
(2.03 log10-fold) than a spore counts from PCR ribotype 027 (P≤0.01) and 002 
(P≤0.05) biofilms. At day three (Figure 4.5.) of biofilm growth, PCR ribotype 002 
had total viable counts were significantly higher than corresponding counts from 
PCR ribotype 078 (1.16 log10-fold) (P≤0.001) and 027 (1.25 log10-fold) (P≤0.001) 
biofilms. Conversely, the spore counts for PCR ribotype 027 were significantly 
more than PCR ribotype 002 (1.71 log10-fold) (P≤0.001) and 078 (1.02 log10-fold) 
(P≤0.05), as were the spore counts for PCR ribotype 078 compared to PCR 
ribotype 002 biofilm (1.69 log10-fold difference) (P≤0.001). 
 
At day six (Figure 4.5.) PCR ribotype 027 had the highest total viable count from 
biofilm which was significantly greater than the corresponding count from PCR 
ribotype 078 (P≤0.001) and 002 (P≤0.01). There was no significant difference 
between the spore counts for PCR ribotype 002 and 027 at day six, however PCR 
ribotype 027 (P≤0.001) and PCR ribotype 002 (P≤0.001) demonstrated 
significantly higher spore counts than those observed in PCR ribotype 078 biofilms.  
 
4.4.3. Comparing Biofilm Growth, Total Viable Counts and Spore Count in 
a 96-Well Microtitre Plate Biofilm Assay 
 
The results for PCR ribotype 078 showed viable count (4.57 log10 CFU/ml to 5.17 
log10 CFU/ml; P≤0.001), spore count (3.96 log10 CFU/ml to 4.58 log10 CFU/ml; 
P≤0.001) and OD590 (0.12 OD590 to 0.28 OD590; P≤0.001) increases between three 
to six days. This is not true for PCR ribotype 027 which showed an increase in 
viable count (4.94 log10 CFU/ml to 5.87 log10 CFU/ml; P≤0.001) and spore (4.02 
log10 CFU/ml to 5.32 log10 CFU/ml; P≤0.001) counts but absorbance results 
plateaued between three and six days (0.12 OD590 to 0.08 OD590; P=0.30). PCR 
ribotype 002 results showed an increase in spore count (2.34 log10 CFU/ml to 5.27 
log10 CFU/ml; P≤0.001), whereas the total viable count (5.71 log10 CFU/ml to 5.70 
log10 CFU/ml; P=0.96) and absorbance (0.07 OD590 to 0.08 OD590; P=0.58) 
plateaued over six days (Figure 4.5. and Appendix 1.4). The viable count was 
significantly higher than spore count for all PCR ribotypes at all-time points 
(P≤0.001) (Appendix 1.4). 
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4.4.4. Biofilm Minimum Inhibition Concentration and Minimum Biofilm 
Eradication Concentrations 
 
There was no difference between all of the PCR ribotypes bMIC and MBEC results 
for both antibiotics (Table 4.1). The same is true for the differences between the 
bMIC and MBEC for both antibiotics for all the PCR ribotypes (Table 4.1).  
 
4.4.5. Comparing bMIC, MBEC and MIC 
 
There was a significant difference between the planktonic MIC and bMIC and 
planktonic MIC and MBEC for metronidazole for all the PCR ribotypes. The 
geometric mean planktonic metronidazole MIC for PCR ribotype 078 (0.08 mg/L) 
was significantly lower than the bMIC (0.05 mg/ml) (P≤0.001) and MBEC (0.57 
mg/L) geometric mean (P≤0.001). This is also true for the results for PCR ribotype 
002 (MIC: 0.18 mg/L) (bMIC: P≤0.001; MBEC: P≤0.001). Whereas, the PCR 
ribotype 027 planktonic MIC (1.37 mg/L) was significantly higher than the bMIC 
(P≤0.001) and MBEC (P≤0.05). The vancomycin MIC results for all PCR ribotypes 
(PCR ribotype 078: 0.57 mg/L; 027: 0.53 mg/L; 002: 0.53 mg/L) were similar to 
the bMIC results (PCR ribotype 078: P= 0.30; 027: P=0.34; 002: P=0.88) and 
MBEC results (PCR ribotype 078: P=0.74; 027: P=0.34; 002: P=0.07) (Table 3.3. 
and Table 4.1.).   
 
4.4.6. Biofilm Total Viable Count and Spore Count in a Static Calgary 
Biofilm Device Assay    
 
PCR ribotype 078 total viable counts and spore counts results stayed constant 
throughout the experimental period (Figure 4.6.). There was not a significant 
difference between viable count and spore count for PCR ribotype 078 at each 
time point (day zero: P=0.15; day two: P=0.50; day four: P=0.07) (Figure 4.6.). 
The viable count results for PCR ribotype 027 also remained constant however 
there was a significant increase in spore count as the experiment progressed 
(P≤0.001) (Figure 4.6.). There was no significant difference between viable count 
and spore count at any time point for the PCR ribotype 027 results (Figure 4.6). 
PCR ribotype 002 total viable counts and spore counts increased significantly over 
the course of the experiment (P≤0.05) (Figure. 4.6.).There was not a significant 
difference between the PCR ribotype 002 spore count and viable count at any of 
the days tested (Figure 4.6.). 
 
4.4.7. Static versus Agitated Calgary Biofilm Device Biofilm Assays 
 
Agitation of the CBD significantly increased formation of biofilms for all C. difficile 
PCR ribotypes, including total viable counts and spore counts (PCR ribotype 078 
and 002: viable count and spore count: P≤0.01, PCR ribotype 027: viable count 
and spore count: P≤0.001) (Figure 4.7).
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Table 4.1. The geometric mean and range for biofilm minimum inhibitory concentration (bMIC) and 
minimum biofilm eradication concentration (MBEC) for PCR ribotype (RT) 078, 027 and 002 groups 
(N=11 strains of each PCR ribotype) for vancomycin (Van.) and metronidazole (Met). Determined using 
a Calgary Biofilm Device over four days in supplemented Brain Heart Infusion broth.  
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Figure. 4.6. Average Viable count (VC) and Spore count (SC) (log
10
 colony forming unit (CFU)peg (±SE)) in biofilms 
formed on a static Calgary Biofilm Device at zero, two and four days of growth, for PCR ribotype (RT) 078, 027 and 
002 in supplemented Brain Heart Infusion broth. 
 
* statistically significant difference P-value ≤0.05 
** statistically significant difference P-value ≤0.01 
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Figure 4.7. Total viable count (VC) and spore count (SC) (log
10
 colony forming unit (CFU)/peg (±SE)) in biofilms 
formed on a static or agitated (1300 rpm) Calgary Biofilm Device over four days of growth, for PCR ribotype (RT) 078, 
027 and 002 in supplemented Brain Heart Infusion broth. 
 
** statistically significant difference P-value ≤0.01 
*** statistically significant difference P-value ≤0.001 
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4.4.8. Comparison of Geographical Location  
 
The biofilm growth results for the PCR ribotype 078 group had no substantial 
variation between locations The bMIC and MBEC showed no substantial variation 
between locations of isolation as most the results for all three PCR ribotypes for 
both metronidazole and vancomycin were ≤0.5 mg/L (Appendix 1.5). 
 
4.5. Discussion and Conclusion  
 
Biofilms are the most common state for bacteria, as they give better protection to 
the bacteria within, from changes in the surrounding environment such as 
antibiotic therapy (Ðapa et al., 2013). The aims of this study were to determine if 
differences existed in biofilm production between three C. difficile PCR ribotype 
groups (PCR ribotype 078, 027 and 002) and also to determine if differences 
existed in biofilm susceptibility to metronidazole and vancomycin between these 
PCR ribotype groups. This was done by growing the biofilm over three and six 
days, then staining them with crystal violet, once washed, the staining was 
leeched out with methanol and the absorbance was read. The susceptibility of 
biofilms to metronidazole and vancomycin was also determined by growing 
biofilms for four days on a CBD, then placing the CBD into a concentration of 
antibiotics overnight, the absorbance was read of the antibiotic solution to find the 
bMIC. The CBD lid was placed into fresh BHIS overnight and the absorbance was 
read to find the MBEC.  
 
PCR ribotypes 078 and 002 both showed an increase in biofilm mean biomass 
between three and six days of growth (only PCR ribotype 078 was significant), 
which is consistent with Lipovsek et al. (2013) who found that all PCR ribotypes 
they studied (including PCR ribotypes 078 and 027) had the potential to produce 
EPS matrix. However, Lipovsek et al. (2013) also demonstrated, that after two 
days of growth there was no EPS matrix present, whereas, after a five day growth 
period there was. Whereas, the results from the present study, for PCR ribotype 
027, there was an insignificant decrease in the absorbance readings between three 
and six days, however Ðapa et al. (2013) found a significant decrease in biofilm 
biomass, of a PCR ribotype 027 strain (R20291), between 24 hours and three days 
of growth and a noticeable decrease between three days and five days. It is 
reasonable to assume that a decrease could have occurred between five and six 
days, which were observed in the present study. Hammond et al. (2014) also 
found PCR ribotype 027 had a decrease in biofilm biomass between 24 and 48 
hours, it could be assumed that the trend would continue over six days. This study 
used the same process as the present study, however Hammond et al. (2014) 
used Reinforced Clostridial Medium broth and glutaraldehyde solution to fix the 
biofilm. Interestingly, C. difficile maybe inefficient in adhering to a 96-well 
microtitre plate compared to other anaerobic bacteria, Donelli et al. (2012) 
described C. difficile as moderately adhering to the bottom of a 96-well microtitre 
plates compared to other Gram-positive anaerobes, such as: C. perfringens and 
Finegoldia magna, and Gram-negative anaerobes, such as:  B. fragilis and 
Prevotella intermedia. 
 
Biofilms were grown for three and six days for all the isolates, to find the total 
viable counts and spore counts within the biofilms. The viable counts for all PCR 
ribotypes significantly increased between three and six days (Figure 4.5). 
Contrastingly, (Dawson et al., 2012) observed more living cells within a three day 
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old biofilm than within a six day old biofilm. The study also used a similar method 
to the present study and  observed less vegetative cells in six day biofilms than 
three day biofilms, and the spore counts increased over six days, which confirms 
the results found in the present study (Dawson et al., 2012). PCR ribotype 027 
biofilms increased in viable counts and spore counts over three days of growth 
this is supported by Crowther et al. (2013) which also found an increase in both 
counts when a biofilm was grown in BHI broth. Growth of C. difficile in a 96-well 
microtitre plates compared to larger 24-well microtitre plates or larger 24-well 
microtitre plates or batch cultures in universal bottles, may potentially have 
affected growth dynamics and subsequent biofilm production. However, due to 
time constraints and difficulties in methods, such as constantly removing the 
microtitre trays from the anaerobic cabinet, which could have a considerable effect 
on C. difficile growth, this study was unable to conduct such experiments. 
 
All viable counts results were significantly higher than the spore count results for 
all PCR ribotypes at every time point in the 96-well microtitre plates. This suggests 
there was a persistent population of vegetative cells throughout the experimental 
period. The day three results are supported by Semenyuk et al. (2014) who found 
more vegetative cells than spores within a three day old biofilm for all the strains 
in their study (including two strains of PCR ribotype 027). The present studies day 
six results are different than the results found in Semenyuk et al. (2014), whose 
results showed more spores than vegetative cells in a day six biofilm. The present 
study’s results are also contradicted by Dawson et al. (2012), who found that 
there were more vegetative cells than spores in a biofilm produced by a PCR 
ribotype 027 (R20291) and strain 630Δerm at three days of growth. Whereas, at 
six days of growth there are more spores than vegetative cells for R20291 biofilm, 
this is not the case for 630Δerm biofilm. These results may differ due to differences 
in the methods used, for example Dawson et al. (2012) grew the biofilms in BHIS 
broth in tissue culture flasks, once diluted in PBS the cells and spores were spread 
on BHIS (supplemented with taurocholate), whereas in the present study the 
biofilms were grown in 96-well microtitre plates and grown on Brazier’s agar.     
      
There was not a significant difference between the total viable counts in biofilms 
produced by PCR ribotype 027 and 078 however PCR ribotype 002 demonstrated 
significantly more viable cells than both PCR ribotype 027 and 078 at day three. 
However, at day six PCR ribotype 027 had significantly more than the other two 
PCR ribotypes and PCR ribotype 078 had the lowest total viable count. (Dawson 
et al., 2012) found strain R20291 had significantly higher viable counts than strain 
630Δerm after both three and six days of biofilm growth. The differences maybe 
explained due to in the methods as described previously.   
  
PCR ribotype 027 and 078 spore counts were significantly higher, at day three of 
growth than PCR ribotype 002 counts, and also after six days of biofilm growth. 
PCR ribotypes 027 and 002 sporulated to a significantly greater degree than PCR 
ribotype 078.  Burns et al. (2011) also found cultures for PCR ribotype 027 strains 
had a significantly higher spore count than the that of non-PCR ribotype 027 
strains after two days of growth and higher spore counts after five days, although 
they did not reach statistical significance. The present study found at six days, 
PCR ribotype 002 had a significantly higher spore count than PCR ribotype 078, 
this is supported by Cheng et al. (2011), who found that PCR ribotype 002 isolates, 
from patients, had a higher frequency of sporulation than non-PCR ribotype 002 
strains, however, this study differed substantially from the present study in the 
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methodology of determining the viable counts. Semenyuk et al. (2014) 
demonstrated no difference between the sporulation of PCR ribotype 027 within 
biofilms compared to biofilms of a non-PCR ribotype 027 strain, however 
substantial differences in the methods utilised (culture media and spore assay 
protocol) may contribute to the difference in results.  
 
Crystal violet (CV) staining was utilised to estimate total biofilm biomass, but this 
method stains both the EPS matrix and bacterial cells (dead or alive) but not 
spores (Kozuka and Tochikubo, 1991; Kwasny and Opperman, 2010; Pantanella 
et al., 2013). In a PCR ribotype 027 biofilm, total viable and spore counts 
increased whereas the biomass plateaued this suggests sporulation was occurring 
within the biofilm, as the spores being produced do not take up the CV, and is 
possible additional EPS matrix was not being produced in the latter stages of 
biofilm formation (Appendix 1.4). PCR ribotype 002 biofilms showed an increase 
in spore count and a plateau in total viable count and biomass, this suggests again, 
sporulation was occurring and additional EPS matrix may not have been produced 
in the latter stages of biofilm formation (Appendix 1.4).  Ðapa et al. (2013) showed 
different results to the present studies results, the study produced graphs showing 
the absorbance (A570) and viable counts (CFU/ml) for strain 630Δerm and strain 
R20291; both graphs showed the viable count results decreasing as the biomass 
plateaued between three and five days, there was not a difference in methods 
used in this study or the present study so the difference in results could be due to 
the strains used. However, the results of Dawson et al. (2012) are consistent with 
the results produced by PCR ribotype 078 in the present study, the paper showed 
an increase in viable and spore count and biomass between three and six day of 
biofilm growth, in strain 630Δerm and R20291 (Appendix 1.4).  However, it cannot 
be stated definitively if elevated EPS matrix was being produced in PCR ribotype 
078 biofilms as the total viable counts and spore counts from biofilms were 
collected from different experiments. Further studies are required to confirm these 
data.      
 
The present study showed that there was not a significant difference between any 
of the vancomycin biofilm MIC results (Table 4.1.). This suggests PCR ribotype 
does not influence C. difficile susceptibility in a biofilm state when exposed to 
vancomycin. When compared to other Gram-positive bacteria, such as 
Enterococcus faecium and S. aureus, the C. difficile MBEC results, in the current 
study, are comparatively low (Holmberg and Rasmussen, 2014; Meije et al., 
2014). Holmberg and Rasmussen (2014) found E. faecium MBEC results, when 
exposed to vancomycin, ranged from 256 mg/L to 512 mg/L. However, Meije et 
al. (2014) found the MBEC for two strains of S. aureus (methicillin-susceptible S. 
aureus (MSSA) and MRSA) were more than 2000 mg/L when exposed to 
vancomycin. When comparing the MBEC and bMIC to the planktonic cell MICs 
(Table 3.2), the planktonic vancomycin MICs for each PCR ribotype were similar 
to the biofilm MIC results (Table 3.2 and Table 4.1). These observations contradict 
those of Antunes et al. (2011) whose study showed that the MIC for vancomycin 
against some Staphylococcus species was significantly lower than the MBEC 
produced. The current study are also different to the observations of Soriano et 
al. (2009), which found the MIC for vancomycin against the Gram-positive 
bacterium Corynebacterium urealyticum was approximately 22 times less than the 
MBEC (Soriano et al., 2009; Soriano et al., 1995). The difference in methods and 
bacterial species used in the current study to find the bMIC and BMEC (Table 4.1.) 
and MIC (Table 3.3.) could contribute to the differences in results and also there 
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is little C. difficile biofilm susceptibility work in the published literature to compare 
to. Additionally, C. difficile may be a comparatively weaker biofilm forming 
organism than these other bacterial species therefore less antimicrobial may be 
required to kill biofilms containing less biomass. 
 
The metronidazole bMIC and MBEC results were similar for all the PCR ribotypes 
(Table 4.1.). Other anaerobic bacterial biofilm, such as those produced by 
Gardnerella vaginalis are affected by metronidazole treatment. For example, 
McMillan et al. (2011) found that 6 mg/L of metronidazole made holes in G. 
vaginalis biofilms and Swidsinski et al. (2008) found treatment with metronidazole 
temporarily suppressed G. vaginalis biofilms. When compared to the planktonic 
MICs, the bMIC and MBEC for PCR ribotype 078 and 002 were significantly less 
than the MICs, whereas the PCR ribotype 027 MICs were significantly higher, than 
the bMIC and MBEC results (Table 4.1. and Table 3.3.). This is, partly, supported 
by Wright et al. (1997) who found the anaerobic bacteria Porphyromonas 
gingivalis had a lower planktonic MIC  (0.375 mg/L) compared to its bMIC (20 
mg/L) for metronidazole (Diaz et al., 2006). This was also true in Larsen (2002), 
which found P. gingivalis (ATCC 33277) had a bMIC of 4 mg/L, whereas, the 
planktonic MIC was 1 mg/L. The difference between the methods employed in the 
current study and the study of Larsen (2002) could contribute to the differences 
in results for the bMIC and BMEC (Table 4.1.) and the MIC (Table 3.3.). 
 
Differences within the results for biofilm growth of each isolate within all three 
PCR ribotypes seem to not be influenced by location of isolation (Appendix 1.5). 
The MBEC and bMIC results showed no variation between the individual isolates 
within each PCR ribotype group (Appendix 1.5). 
 
The Calgary biofilm device (CBD) has not been used previously to assess C. difficile 
biofilm formation and antimicrobial susceptibilities. The observations that some C. 
difficile PCR ribotypes grow as pellets of growth at the bottom of cultures tubes 
(for example PCR ribotype 078) (Figure 2.4.), suggested that the CBD may not be 
an optimal method for the study of biofilm susceptibilities in C. difficile. In order 
to address the potential lack of motility of certain C. difficile PCR ribotypes, the 
similar planktonic and biofilm MICs demonstrated previously (see Table 3.2 and 
Table 4.1), a study was undertaken to quantify biofilms on CBD pegs in static and 
agitated CBD experiments. The results of the present study indicated that total 
viable count and spore counts on a static CBD over four days of growth for all PCR 
ribotypes remained constant. Ali et al. (2006) found a significant increase in 
biofilm production between 24 and 48 hours, when E. coil and Listeria innocua 
were grown on CBDs, they also found after two days of growth both bacteria (5.78 
log10 count/peg ±0.064) had noticeably more viable cells than were observed at 
day two in the present study (1.63 log10 CFU/peg±0.64). There was also an 
increase in biofilm production (over 25 hours) when Ceri et al. (1999) grew E. coli 
(ATCC 25922) and P. aeruginosa (ATCC 27853) on CBDs. The µmax of the E. coli 
(planktonic µmax= 1.73 h-1), L. innocua (planktonic µmax =0.78 h-1) and P. 
aeruginosa (planktonic µmax= 0.74 h-1) could have an influence on biofilm 
production, as the faster the growth the sooner biofilm could be produced, 
however the average growth rate for C. difficile (0.63 h-1) from this study, was 
lower than the growth rates of the other bacteria (Cox, 2004; Folsom et al., 2010; 
Shama et al., 2005).  
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Spores are resistant to antibiotics so if there are more spores in a biofilm, the 
biofilm may be able to survive antimicrobial therapy (Oka et al., 2012). PCR 
ribotype 078 had significantly more spores in its biofilm (on the CBD) compared 
to PCR ribotypes 027 and 002, however their geometric means for the bMICs and 
MBECs (for vancomycin and metronidazole) were similar. The similarities in the 
results may be due to the number of vegetative cells within a biofilm, as there 
was no significant difference between the viable count for PCR ribotypes 078 and 
the other two PCR ribotypes. There was a significant difference between the biofilm 
spore counts which suggested varying numbers of vegetative cells in the biofilm. 
Therefore, other factors may contribute to similar bMIC and MBEC results such as 
the planktonic antibiotic susceptibility. As the planktonic susceptibility results were 
similar to the biofilm susceptibility results (Table 3.2 and Table. 4.1).  
 
In conclusion, PCR ribotype seemingly does have an effect on the biofilm 
production; it would appear that the hypervirulent PCR ribotypes 078 and 027 
produce more biofilm at three days of growth then the PCR ribotype 002. After six 
days of biofilm growth, PCR ribotype 078 biofilms further increased, in contrast to 
PCR ribotype 002 whereas, PCR ribotype 027 biofilm production decreased 
(although insignificantly). At six days, the viable count and spore count studies 
demonstrated that C. difficile biofilms were composed of a large proportion of 
spores, which would not stain with crystal violet, therefore this may explain why 
OD590 did not increase for some strains at day six. The assessment of other 
methods for quantifying C. difficile biomass may explain this phenomenon further. 
Additionally, all the bMIC and MBEC were similar regardless of PCR ribotype, which 
conflicts with some prior studies and warrants further study to confirm these 
findings and improve the reproducibility of the results obtained. It is possible that 
the CBD is not a suitable experimental system in which to study C. difficile biofilms, 
due to culture settling and the bottom of the microtitre plate wells (Figure 2.4.), 
and no prior studies in C. difficile using this model exist in the literature. However, 
the present study shows that a C. difficile biofilm will grow on a CBD and will grow 
better if the microtitre plate is agitated during the growth period (Figure 4.7). Due 
to biofilms being the natural state for most bacteria and C. difficile being able to 
produce biofilms within the gut (of mice), these results suggest that biofilms 
produced by PCR ribotype 078 in CDI patients could cause the infection to last 
longer, as the PCR ribotypes biofilm production increases between three and six 
days (in vitro) (Crowther et al., 2014; Jefferson et al., 2005; Semenyuk et al., 
2014). Thicker biofilms contain more antibiotic-resistant spores, which also 
increases the likelihood of recurrence of CDI. Thicker C. difficile PCR ribotype 078 
biofilms may be more difficult to eradicate with antibiotics due to reduced drug 
penetration compared to the biofilms of PCR ribotype 027 and 002.   
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5. Main Discussion and Conclusions 
 
C. difficile is an anaerobic, Gram-positive spore-forming bacterium which resides 
in many different environments (Baverud et al., 2003; Lawley et al., 2009). The 
species is classified into over 600 different PCR ribotypes. The present study 
compared three common PCR ribotype groups which were isolated from clinical 
cases of CDI in the UK (Table 1.1.), and are often isolated from the intestinal 
tracts of humans and animals (Janezic et al., 2012). This study aimed to compare 
the growth characteristics, cytotoxin production, antimicrobial susceptibilities, and 
biofilm growth and antimicrobial susceptibilities between these three PCR ribotype 
groups.  
 
PCR ribotype 078, 027 and 002 all cause disease by producing two toxins (toxin 
A and toxin B). These toxins can cause a spectrum of disease including diarrhoea, 
PMC and even death (Debast et al., 2014; Shen, 2012). CDI occurs when the 
normal gut microflora becomes compromised by treatments, such as 
chemotherapy, and most commonly antibiotic therapy, which inhibits the other 
bacteria in the gut and in turn causes C. difficile to thrive (Debast et al., 2014; 
Loo et al., 2011). Treatments for CDI include two antibiotics, metronidazole and 
vancomycin, depending on the severity of the illness. PCR ribotype 078 has 
incrementally increased in prevalence in humans from 2007 to 2013 and has been 
classed, as hypervirulent by Goorhuis et al. (2008), as has PCR ribotype 027 (PHE 
and CDRN, 2014). Both PCR ribotypes have been hypothesised to produce more 
toxin as a consequence of mutations within the PaLoc, and in turn, cause more 
severe illness than other virulent PCR ribotypes (Goorhuis et al., 2008; MacCannell 
et al., 2006). Hypervirulent PCR ribotypes are also thought to be more resistant 
to certain classes of antibiotics, therefore if these antibiotics are used for other 
illnesses, they are more likely to cause CDI. For example, resistance to 
fluoroquinolones has been observed in PCR ribotypes 078 and 027 (He et al., 
2013; Keessen et al., 2013; McDonald et al., 2005).  
 
Toxin production is considered to be the major factor of virulence in C. difficile and 
hypervirulent PCR ribotypes are thought to produce quantitatively more toxin 
therefore cause more severe disease (Curry et al., 2007; Goorhuis et al., 2008; 
Knetsch et al., 2011; Shen, 2012; Warny et al., 2005). The results of the present 
study were interesting in that cytotoxin production by PCR ribotype 078 group was 
elevated in comparison to PCR ribotype 002, and more interestingly the reported 
hyper-toxin producing PCR ribotype 027 (Warny et al., 2005). This could be due 
to the 39-bp mutation within tcdC which has been suggested to negatively 
regulates toxin production (Cartman et al., 2012; Curry et al., 2007; Knetsch et 
al., 2011), although contradictory evidence does exist for the role of tcdC. It may 
be that slightly higher OD600 readings for the PCR ribotype 078 group (up to six 
hours) may have contributed to this to a small degree but at the latter time points 
where cytotoxin expression was observed at higher levels (24 and 48 hours), 
OD600 readings were similar between ribotypes. Low-level cytotoxin production 
was observed sooner in the PCR ribotype 078 group than in the comparator 
groups, therefore this may have contributed to the eventual elevated cytotoxin 
titres in a cumulative fashion. Further studies assessing the level of transcriptional 
activity of the PaLoc genes may help to determine if these observations were 
indeed a consequence of true earlier cytotoxin production or an artefact of in vitro 
experimentation. These results suggest that PCR ribotype 078 could cause illness 
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sooner if these growth characteristics were observed in vivo, and with elevated 
cytotoxin production, CDI of greater severity is a possibility, although prior studies 
have failed to conclusively link toxin levels in faeces of CDI patients with severity 
of disease (Akerlund et al., 2006; Cartman et al., 2012; Curry et al., 2007; 
Knetsch et al., 2011). 
 
Antimicrobial resistance in C. difficile could potentially contribute to a patient 
contracting CDI (Nelson et al., 2011). In the present study PCR ribotype 078, was 
susceptible to most of the antibiotics used in this study including the two 
antibiotics used as treatments for CDI; metronidazole and vancomycin. The 
present study showed PCR ribotype 078 was more susceptible to metronidazole 
(breakpoint ≤8 mg/L; Geometric mean MIC: 0.08 mg/L) than PCR ribotype 027 
(Geometric mean MIC: 1.37 mg/L) but not substantially different in susceptibility 
compared to PCR ribotype 002 (Geometric mean MIC: 0.18 mg/L) (CLSI, 2007). 
Even though these results are not consistent with Moura et al. (2013), who used 
AIM (using Schaedler’s broth and Wilkins-Chalgren agar) to demonstrate that PCR 
ribotype 078 (0.125 mg/L) had very similar metronidazole MIC results to PCR 
ribotype 027 (0.125 mg/L to 0.5 mg/L), as well as other virulent strains, such as 
PCR ribotype 001 (0.125 mg/L to 4 mg/L). Despite its hypervirulent status, PCR 
ribotype 078 remains, potentially, treatable with metronidazole if simple 
antimicrobial susceptibility data are considered alone. A similar scenario was 
observed for the vancomycin (breakpoint ≤2 mg/L) geometric mean MIC results, 
(PCR ribotype 078: 0.57 mg/L; PCR ribotype 027 and 002: 0.53 mg/L) which are 
similar to the results reported by Debast et al. (2013) whose results showed no 
noticeable difference in susceptibility for the PCR ribotype 078 or 027, therefore 
these results, suggest vancomycin could treat CDI caused by PCR ribotype 078 
just as well as if it were caused by PCR ribotype 027 or 002 (Table 3.3.) (EUCAST, 
2014). The clindamycin (susceptibility breakpoint: ≤2 mg/L) geometric mean MIC 
for PCR ribotype 078 (0.09 mg/L) was the lowest out of the three PCR ribotype 
groups assessed in this study (PCR ribotype 027: 0.44 mg/L; PCR ribotype 002: 
3.31 mg/L), concluding PCR ribotype 002 are less susceptible to clindamycin 
(CLSI, 2007). PCR ribotype 078 had a lower geometric mean MIC to erythromycin 
(0.5 mg/L) than PCR ribotype 027 (128 mg/L) and similar results to PCR ribotype 
002 (0.25 mg/L) (breakpoint: >2 mg/L) (BSAC, 2013). Therefore PCR ribotype 
078 is more susceptible to these antibiotics than the other PCR ribotypes. The 
linezolid (breakpoint: >4 mg/L) geometric mean MIC for the PCR ribotype 078 
group (0.73 mg/L) was noticeably higher than PCR ribotype 027 (0.25 mg/L) and 
002 (0.5 mg/L). This is the same for the tetracycline (breakpoint: ≤4 mg/L) results 
(PCR ribotype 078: 0.93 mg/L; PCR ribotype 027: 0.11 mg/L; PCR ribotype 002: 
0.06 mg/L), this could be explained by the tetracycline resistance gene, tetM, 
which PCR ribotype 078 does possess, whereas PCR ribotype 027 does not (Bakker 
et al., 2010; CLSI, 2007; Stabler et al., 2009). Therefore these results show PCR 
ribotype 078 is relatively less susceptible to linezolid and tetracycline than the 
other two PCR ribotypes. This could result in PCR ribotype 078 CDI potentially 
occurring earlier in the course of therapy with these agents, before the gut 
microflora had recovered, than for C. difficile strains which were more susceptible. 
Additionally, PCR ribotype 078 was more susceptible to ciprofloxacin (7.51 mg/L) 
and moxifloxacin (1.07 mg/L) than the other two PCR ribotypes (PCR ribotype 
027: ciprofloxacin (68.16 mg/L) and moxifloxacin (32 mg/L); PCR ribotype 002: 
ciprofloxacin (10.29 mg/L) and moxifloxacin (1.76 mg/L)). Previous studies have 
found both PCR ribotype 078 and 027 may possess mutations in gyrA and/or gyrB 
which have been linked to fluoroquinolone resistance (O'Connor et al., 2009; 
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Rodriguez et al., 2014; Saxton et al., 2009). These results suggest, PCR ribotypes 
078 and 027 (and 002) are both resistant to ciprofloxacin (breakpoint: >1 mg/L) 
but only PCR ribotype 027 was resistant to moxifloxacin (breakpoint: ≥8 mg/L) 
and therefore may have increased risk of causing CDI in moxifloxacin-treated 
patients (BSAC, 2013; CLSI, 2007). It can be concluded by these results that 
antibiotic susceptibly cannot be determined by PCR ribotype, therefore could not 
contribute to the hypervirulent status of PCR ribotype 078, contradictory to 
previous studies, such as Goorhuis et al. (2008), who contributed fluoroquinolone 
resistance to PCR ribotype 078 and 027 hypervirulent status, as all strains in all 
PCR ribotypes were resistant to ciprofloxacin therefore resistance to this antibiotic 
could increase in a clinical setting. Regular screening for resistance will need to be 
performed so resistance to other antibiotics in clinical setting can be monitored 
and changes can be made where possible. 
 
Biofilms are the most common state for most bacteria, and C. difficile produces 
biofilms within the gastrointestinal tracts of mice and also in vitro in simple and 
complex biofilm models, which have been found to increase the antibiotic 
resistance of the bacteria within (Burmolle et al., 2014; Crowther et al., 2014; 
Dawson et al., 2012; Jefferson et al., 2005). Biofilms are thought to potentially 
contribute to the recurrence of CDI, as a mature C. difficile biofilm contains highly 
resistant spores, which are dispersed in the later stage of biofilm production 
(Semenyuk et al., 2014). The present study found that PCR ribotype 078 had 
increased biofilm production between three and six days, compared to PCR 
ribotype 027 which decreased and PCR ribotype 002 where minimal biofilm 
production was observed. The effects of the antibiotics metronidazole and 
vancomycin were assessed in their ability to inhibit C. difficile biofilms using a 
CBD. The results of the present study were difficult to interpret as the bMIC were 
low and comparable to the MBEC. Further testing demonstrated that agitating the 
CBD throughout the growth period, increased viable and spore count. It is possible 
that agitation of the microtitre CBD plates may facilitate better mixing and more 
robust biofilm formation and therefore bMIC and MBEC that reflect similar studies 
in other organisms (Jefferson et al., 2005). Given the apparent greater degree of 
biofilm formation by PCR ribotype 078, if these observations translated to the in 
vivo situation, it could be more difficult to treat these biofilms than those of other 
PCR ribotypes, such as PCR ribotype 027 and 002. PCR ribotype 078 biofilms may 
potentially produce more EPS matrix, therefore be thicker and could be more 
resistant to antibiotic treatment. (Crowther et al., 2014; Semenyuk et al., 2014; 
Stoodley et al., 2002). Experiments with the CBD in pure culture are a 
simplification of in vivo biofilms within the gastrointestinal tract where complex 
biofilms of multiple bacterial species exist (Crowther et al., 2014), therefore 
results from simple pure culture biofilms must be interpreted with some caution. 
Despite this, differences under the same experimental conditions were observed 
for the biofilms of the C. difficile groups assayed in this study which warrant further 
study to assess their significance and reproducibility. 
 
The location of strains appears to have little or no effect on the results for all the 
properties investigated in this study (Appendix 1.5). However, it is hard to demine 
using this study due to the small number of strains from each location, to further 
investigate if location of isolation does influence MIC or biofilm production (for 
examples) more isolates from different locations would have to be studied. This 
will also determine similarities between different regions and counties.   
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In conclusion, in this study that assessed the phenotype of the hypervirulent C. 
difficile PCR ribotype 078 it was observed that a group of PCR ribotype 078 C. 
difficile isolates produced elevated cytotoxin titres and potentially began producing 
low-level cytotoxin earlier in the growth cycle, even when compared to the 
hypervirulent PCR ribotype 027. Furthermore, increased biofilm production by PCR 
ribotype 078 was also observed which could potentially contribute to greater 
difficulty in eradicating C. difficile in vivo if these results were translated in 
patients. The antibiotics, metronidazole and vancomycin, used at present in 
hospitals around UK, were effective against planktonic cells and bacteria within a 
biofilm, during in vitro experiments. Resistance to fluoroquinolones in PCR 
ribotypes 078 and 002, such as ciprofloxacin, could be the result of 
fluoroquinolone selective pressure observed in the clinical setting as a 
consequence of their increasing prevalence in the UK (PHE and CDRN, 2014). 
 
This study adds to the literature published on the hypervirulent PCR ribotype of C. 
difficile. Goorhuis et al. (2008) previously studied PCR ribotype 078 investigated 
the PCR ribotype 078 PaLoc and observed the presence of intact tcdA and tcdB 
genes and a mutation in tcdC, however the study did not investigate the 
production of the toxins compared to other PCR ribotypes. The study of Goorhuis 
et al. (2008) also compared patients with CDI, caused by PCR ribotype 078 and 
027, to see if there were similar characteristics, such as age, severity of illness 
and mortality, and found that patients with PCR ribotype 078 induced-CDI were 
younger but had similar severity of symptoms and mortality rates to PCR ribotype 
027. The present study investigated potential virulence-enhancing traits of C. 
difficile, such as cytotoxin production, and compared two hypervirulent PCR 
ribotypes and a comparator strain (PCR ribotype 002). The present study also 
compared the properties which could contribute to more severe illness and CDI 
recurrence in patients such as growth characteristics, biofilm production, and 
biofilm/planktonic cell susceptibilities to antimicrobial agents. More studies are 
required in order to evaluate PCR ribotype 078 further, in more gut-reflective in 
vitro models or in animal models of CDI.  
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S 
Suspect that a case may be infective where there 
is no clear alternative cause for diarrhoea. 
I 
Isolate the patient and consult with the infection 
control team (ICT) while determining the cause of 
the diarrhoea. 
G 
Gloves and aprons must be used for all contacts 
with the patient and their environment. 
H 
Hand washing with soap and water should be 
carried out before and after each contact with the 
patient and the patient’s environment. 
T 
Test the stool for toxin, by sending a specimen 
immediately. 
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Appendix 1.1. The ‘SIGHT’ protocol is used in hospitals when a patient is suspected 
of having C. difficile infection (DH and HPA, 2008).  
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Appendix 1.2. The natural logarithm (LN) of mean OD
600
 (±SE) in batch culture growth in supplemented Brain Heart 
Infusion broth of C. difficile PCR ribotypes (RT) 078, 027and 002 (N=11 of each PCR ribotype) between 2 and 6 hours. 
Showing the maximum specific growth rate (h
-1
) for each PCR ribotype.  
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Appendix 1.3.  Biomass (optical density (OD)
600
 (±SE)) and median cytotoxin titre (relative units, RU (±SE)) for PCR 
ribotypes (RT) 078, 027 and 002 (N=11 strains of each PCR ribotype) grown in supplemented Brain Heart Infusion 
broth. 
*** statistically significant difference P-value ≤0.001 
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Appendix 1.3.  Biomass (optical density (OD)
600
(±SE)) and median cytotoxin titre (relative units, RU (±SE)) for PCR 
ribotypes (RT) 078, 027 and 002 (N=11 strains of each PCR ribotype) grown in supplemented Brain Heart Infusion broth. 
*** statistically significant difference P-value ≤0.001 
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Appendix 1.5. Results for each individual isolate for PCR ribotype (RT) 078, 027 and 002, including the two control strains (E4 
and ATCC 700057) as well as strain number and location of isolation. The results are for specific growth rate (µmax) (h-1), median 
cytotoxin production (relative units, RU) at 24, 48 and 72 hours (h), minimum inhibitory concentration (MIC) (mg/L) for 
metronidazole (Met.), vancomycin (Van.), ciprofloxacin (Cip.), clindamycin (Clind.), erythromycin (Ery.), linezolid (Lin.), 
moxifloxacin (Mox.) and tetracycline (Tet.), as well as biofilm MIC (bMIC) and minimum biofilm eradication concentration (MBEC) 
(mg/L) for Met. and Van. and biofilm average biofilm growth (OD590) at 3 and 6 days (D) of growth.   
  
1
0
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Word count: 28 743 
   
 
